Accuracy of Pulmonary Artery Acceleration time derived by Doppler Echocardiography in predicting Pulmonary Artery Pressures. by Jegadeeswari, A
 
 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU 
 
ACCURACY OF PULMONARY ARTERY ACCELERATION TIME 
DERIVED BY DOPPLER ECHOCARDIOGRAPHY IN 
PREDICTING PULMONARY ARTERY PRESSURES 
 
 
 
 
 
 
 
 
 
 
 
Dissertation submitted for DM 
(Branch II – Cardiology) 
 
August 2013 
 
 
CERTIFICATE 
 
This is to certify that this dissertation titled “ACCURACY OF PULMONARY ARTERY 
ACCELERATION TIME DERIVED BY DOPPLER ECHOCARDIOGRAPHY IN 
PREDICTING PULMONARY ARTERY PRESSURES ”, submitted by  Dr.A.Jegadeeswari,  
to the faculty of Cardiology, The Tamilnadu Dr.M.G.R.Medical University, Chennai in partial 
fulfillment of the requirement for the award of DM degree, Branch II [Cardiology] is a bonafide 
research work carried out by her under my direct supervision and guidance.  
 
 
 
 
                                                                                                                      
Professor and Head  
Department of Cardiology 
Madurai Medical College and 
Government Rajaji Hospital, Madurai 
 
 
 
 
 
 
 
 
 
DECLARATION 
 
I, Dr.A.Jegadeeswari, solemnly declare that the dissertation titled “ACCURACY OF 
PULMONARY ARTERY ACCELERATION TIME DERIVED BY DOPPLER 
ECHOCARDIOGRAPHY IN PREDICTING PULMONARY ARTERY 
PRESSURES ” has been prepared by me. This is submitted to The Tamilnadu 
Dr.M.G.R.Medical University, Chennai, in partial fulfillment of the regulations for the 
award of DM degree, Branch II [Cardiology].  
 
 
 
 
 
Madurai.                                          Dr.A.Jegadeeswari  
Date:        
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
My sincere thanks to our Dean, Prof. Dr. N. Mohan, M.S., for permitting me to use 
the facilities of Govt. Rajaji Hospital and Madurai Medical College to conduct this study. 
I am indebted to my beloved Professor and Head of the Department of Cardiology, 
Prof. Dr.R.A.Janarthanan, M.D.,D.M., who had guided me throughout the conduct of the 
study and also during the postgraduate course. I thank him profusely and sincerely. 
My sincere thanks to my Prof. Dr. A.S. Arul, M.D.,D.M., Addl. Professor of 
Cardiology, for his valuable support throughout the study and also in the D.M. course. 
I shall ever remain in gratitude to my teachers, Prof. Dr. V.A. Amuthan, 
M.D.,D.M.,FACC, and Prof. Dr. S. Murugan,M.D.,D.M., retired Professors of 
Cardiology, Govt. Rajaji Hospital and Dr. S.Balasubramanian,M.D.,D.M., and Dr. 
R.Aravazhi, M.D.,D.M., former Asst. Professors of Cardiology, Govt. Rajaji Hospital. 
Knowledge and kindness abound my beloved teachers, Dr. S. Naina Mohammed, 
M.D.,D.M., Dr. N.Ganesan, M.D.,D.M., Dr. G.S. Sivakumar, M.D.,D.M. and Dr. S.R. 
Veeramani, M.D.,D.M.. I owe them a lot and sincerely thank them. 
I am thankful to all my colleagues for their valuable support to help complete the 
study. 
Above all, I am indebted to all the patients who participated in the study. Without 
them, this work would not have been possible. My sincere thanks to them. 
 
 
TABLE OF CONTENTS 
 
 
 
S. No. TITLE Page No. 
1 INTRODUCTION 1 
2 AIM OF THE STUDY 37 
3 MATERIALS AND METHODS 38 
4 RESULTS 45  
5 DISCUSSION 60 
6 LIMITATIONS OF THE STUDY 65 
7 CONCLUSION 66 
 BIBLIOGRAPHY  
 APPENDIX  I  : PERFORMA  
 APPENDIX  II  - MASTER CHART   
 
 
INTRODUCTION 
Two decades ago pulmonary hypertension (PH)  was seen as a serious illness with 
a survival of 2.8 years from its diagnosis. Significant progress has been made in this field 
in the last ten to fifteen years in the understanding of the pathophysiology and also the 
treatment of PH. In the past, even though physicians diagnosed PH, treatment of this 
condition was not rewarding and patients almost always succumbed to the disease. The 
discovery of prostacyclin by Sir John Vane has since made a revolution in the treatment 
of PH1.  
PH is a disease that results from reduction in the  quantity of blood flowing across 
the pulmonary circulation, that causes an increase in pulmonary vascular resistance 
(PVR) and ultimately to right ventricular failure2 Excessive proliferation of the 
endothelial lining cells of the pulmonary vasculature and reduced apoptosis of the same 
leads reduction in the luminal cross sectional area  of the pulmonary arterial tree. This 
results in increased pulmonary vascular resistance(PVR). Abnormal and inappropriate 
vasoconstriction is also implicated in about 20% of patients.3,4  
PH occurs in many different clinical conditions and the hemodynamic abnormality 
leads to right ventricular (RV) pressure overload. The clinical disease producing PH, the 
type of vascular pathology and the severity of the lesions determine the natural history 
of PH, the clinical features and its potential reversibility: PH caused by chronic hypoxia is 
mainly due to muscularization of the small muscular pulmonary arteries. The 
endothelium is not much affected. Correction of hypoxia leads to reversal of PH. As 
 
 
opposed to this, systemic sclerosis causing PH progresses relentlessly because the 
vascular pathology involves the intimal layer mainly, leading to vascular obstruction. 
And in pulmonary capillary hemangiomatosis, the main pathological lesions are seen in 
the pulmonary capillary bed. 
Because of its great distensibility, large capacity, low resistance to blood flow, and 
the very modest amounts of smooth muscle in the small arteries and arterioles, usually 
the pulmonary circulation is not predisposed to become hypertensive. But when the 
total cross-sectional area of the pulmonary circulation is decreased by destruction of 
lung tissue or occlusive lesions in the resistance vessels, pulmonary arterial pressures 
rises. The degree of PH that develops is thus a function of the amount of the pulmonary 
vascular tree that has been affected or eliminated.  
PH is the result of heart or lung disease, commonly. Although idiopathic 
pulmonary artery hypertension (IPAH) is uncommon, it is well recognized as a unique 
clinical entity where the intrinsic pulmonary vascular disease is free from the 
complicating features of PH contributed by diseases of the heart and/or lungs.  
Mild PH can exist for a lifetime without becoming evident clinically. Native 
residents at a high altitude, in whom mild to moderate PH is due to sustained exposure 
to hypoxia, can adapt and function normally. When pulmonary hypertension does 
become manifest clinically, the symptoms tend to be nonspecific. 
Patients with severe PH have a poor prognosis, in the absence of treatment. But 
the recent drugs used for the treatment of PH have shown a beneficial influence on the 
 
 
survival rate in several recent meta analyses of trials5. The understanding of the disease 
pathways in PH have improved notably in the recent times. This has paved the way for 
newer therapeutic strategies: use of prostaglandins, inhibition of PDE-5 and the 
antagonism of endothelin receptors. In the near future, newer drugs which are now 
being tested in pre clinical studies may become available: inhibitiors of pyruvate 
dehydrogenase kinase, the antiapoptotic protein survivin, the serotonin transporter (5-
HTT); several transcription factors (HIF-1 alpha and nuclear factor activating T 
lymphocytes [NFAT]), and also drugs that augment the voltage-gated potassium channel 
channels (e.g., Kv1.5). Other drugs for treatment of PH which are in their infancy of 
development include vasoactive intestinal peptide(VIP) and tyrosine kinase inhibitors. 
Administration of stem cells and angiogenic factors and drugs that target the 
mitochondrial dysfunction also have therapeutic promise in the future. 
Normal Pulmonary Circulation 
Structure 
Just before birth, pulmonary and systemic arterial blood pressures are nearly 
equal at about 70/40 mmHg, with a mean of 50 mmHg. Immediately after birth, with 
the closure of ductus arteriosus and the initiation of ventilation, pulmonary arterial 
pressure rapidly falls to about one-half of systemic levels. After that, the pulmonary 
arterial pressures gradually reduce over several weeks to reach adult levels. 
In some new born, the normal PH of the fetus fails to recede normally, as a result 
of either a developmental anomaly or a persistent increase in pulmonary vascular tone. 
 
 
In such neonates, the persistent pulmonary hypertension and the RV failure may 
become life-threatening. Temporizing measures, like the use of inhaled nitric oxide (NO) 
or extracorporeal membrane oxygenation or surgical intervention , might be useful in 
reversing the pulmonary vascular abnormalities. 
In normal adults at sea level, the small muscular arteries and arterioles in the lungs 
are thin-walled and have very little smooth muscle. But in the fetus or in the adult who 
has lived under hypoxic conditions (residents of high altitude), the media of the 
arterioles are more thick, and the muscle also extends distally into the precapillary 
vessels that are normally devoid of muscle - the precapillary vessels undergo 
"remodeling." 
Endothelium and Endothelium–Smooth Muscle Interactions in the lungs 
The endothelium is a semipermeable membrane that acts as a barrier between 
blood and the pulmonary interstitium. It has  many other biologically important 
functions, the net effects of which are the processing of blood flowing through the 
lungs: it the synthesises and processes many vasoactive substances; modulates 
coagulation and thrombolysis; transduces many  blood-borne signals; regulates cell 
proliferation; participates  in immune reactions; engages in the local inflammatory 
reactions to injury; and also involves in angiogenesis. Endothelium is thus regarded as 
an organ with diverse metabolic and endocrine functions. Importantly, the largest area 
of endothelium in the body is contributed by the lungs. 
 
 
The cells that make up the monolayered endothelial lining communicate with the 
smooth muscle cells in the medial layer through many biologically active substances. 
This interaction between the two layers of cells regulates the normal vasomotor tone. It 
also determines the response of the vasculature to the administration of vasodilating 
drugs used for the treatment of PH. Endothelial cell injury and the resultant 
proliferation of the intima and the hypertrophy of the underlying smooth muscle cells 
upset this normal interaction and alter the hemodynamics. 
Pulmonary Hemodynamics in health 
In adults, the value of normal pulmonary arterial pressure depends on the altitude. 
At the sea level, with a cardiac output of 5 to 6 L/min the normal pulmonary arterial 
pressure is about 20/12 mmHg, with a mean of 15 mmHg. At an altitude of 15,000 ft,  
the same cardiac output is associated with slightly higher pulmonary pressures. 
Pulmonary arterial pressures also tend to increase with age. 
Table 1:  Values for Normal Pulmonary Circulation at Sea Level and High Altitude 
 
 Sea Level Altitude (~15,000 
ft) 
Pulmonary arterial pressure mmHg 
20/12, 15 38/14, 25 
Cardiac output (Q), L/min 6 6 
Left atrial pressure , mmHg 5 5 
Pulmonary vascular resistance (mmHg/L)/min (R 
units) 
 
1.7 3.3 
 
 
Determination of PVR, calculated as :  (pulmonary arterial pressure - LA pressure) / 
cardiac output, is a practical clinical method for assessing the pulmonary hemodynamics 
and for assessing vasoreactivity (the effect of administering a vasodilator agent in a 
patient with PH). Pulmonary artery wedge pressure is usually substituted for LA 
pressure. 
In the normal lung, a considerable rise in cardiac output, increases pulmonary 
arterial pressure by only a few mm of Hg. But in PH, in which the recruitability of the 
pulmonary vascular bed and its distensibility are restricted by disease, pulmonary 
arterial pressure rises with even small increase in pulmonary blood flow. Changes in 
pulmonary blood volume are subtler than changes in pressure or flow in their 
hemodynamic effects.  
Autonomic innervation of the pulmonary arteries plays a less significant role in 
regulating vasomotor tone than do local stimuli, particularly hypoxia. The mechanism of 
vasoconstriction due to hypoxia exerts is not fully understood but likely involves altered 
smooth muscle cell membrane ion channel activity. Acidosis potentiates this effect. 
Hypercapnia has a vasoconstictive effect on the pulmonary tree, by causing local 
acidosis. But it is a less powerful pulmonary vasoconstrictor agent. 
Pulmonary Hemodynamics in disease 
To differentiate among the various causes of PH, a detailed measurement of all the 
indices of pulmonary  hemodynamics is important.  
 
 
In PAH the  pulmonary arterial pressures and the PVR are markedly elevated, while 
the pulmonary capillary wedge pressure, is usually normal. Congenital heart diseases, 
with left to right shunts are a common cause of PAH. Eisenmenger syndrome is 
characterized by PAH in its most advanced form of associated. A large left to right shunt 
present initially causes progressive pulmonary vascular disease and PAH, and 
subsequent reversal of the shunt. 
The main alteration in PH due to left-heart disease is a significant increase in 
pulmonary wedge pressure; pulmonary arterial pressures show only a mild to moderate 
increase , and PVR is usually normal. Occasionally, PAP is markedly increased, and hence 
PVR is also increased. Diseases of the left heart like valvular diseases, LV systolic 
dysfunction, LVdiastolic dysfunction etc. can lead to PH. 
In the presence of obstructive or restrictive lung diseases, PH is usually moderate, 
and PVR is moderately elevated. PCWP is normal or mildly elevated, in the absence of 
concomitant left heart disease. A similar pattern is seen in residents at high altitude, due 
to the effect of chronic hypoxia. 
The pulmonary arterial pressures and PVR are elevated only to a  mild to moderate 
degree in acute pulmonary embolism; PCWP is normal unless concomitant left-heart 
disease is present; the degree of elevation in PAP and PVR strongly correlate with the 
amount of pulmonary vascular obstruction. 
Chronic pulmonary thromboembolic hypertension(CTEPH) occurs in about 4% to 
5% of patients after an index episode of acute pulmonary embolism.  The pulmonary 
 
 
hemodynamics in CTEPH is similar to that of PAH; PAP and PVR are markedly increased, 
while PCWP is normal. To establish the diagnosis of chronic thromboembolic PH is of 
great clinical importance because it has got significant therapeutic implications : 
pulmonary endarterectomy in such cases reverses PH to a significant degree and results 
in marked clinical improvement. 
DEFINITION OF PULMONARY HYPERTENSION 
The fourth World Symposium on PH was held at Dana Point in 2008, where new 
cutoffs  of mean pulmonary artery pressure (MPAP) for the diagnosis of PH were 
introduced. An MPAP < 21 mm Hg is normal;  from 21 to 25 mm Hg is categorized as 
borderline,  and >25 mm Hg is designated as PH. Correspondingly,  echocardiographic 
maximum tricuspid regurgitant velocity (TRVmax) <2.5m/s is defined as normal, 2.5 to 
2.8 m/s as borderline, and >2.8 m/s is defined as PH. Thus, PH has been defined as an 
increased MPAP more than 25 mmHg at rest as assessed by right heart 
catheterization6,7.  
Table2 : New cutoff  values for the diagnosis of PH: 
Invasive(MPAP) Normal < 21mm Hg 
Borderline 21 – 25 mm Hg 
Manifest >25 mm Hg 
Non invasive(TRVmax) Normal <2.5m/s 
Borderline 2.5-2.8m/s 
Manifest > 2.8m/s 
 
 
 
 In a number of RCTs and registries of PAH the above mentioned values of MPAP 
has been used for randomising patients.8,9 Recent analysis of the data available  so far 
has revealed that the normal MPAP at rest is 14±3 mmHg, the upper limit of normal 
being  20 mmHg.10,11 The significance of a value of MPAP between 21 and 24 mmHg is 
not clear. Patients with a PAP between 21 and 24 mm Hg need evaluation in future 
epidemiological studies. The definition of PH on the basis of a post exercise value of  
MPAP >30 mmHg as measured by RHC has not been backed by the published data so 
far, as the MPAP in healthy individuals reach much higher values.10,12 
INCIDENCE 
The estimated incidence of PH range from one to two cases per million in the 
general population13. The incidence of PAH in HIV infection and in portal hypertension 
has been estimated to be between 0.5% and 2%.14 The familial form of PAH does not 
differ much from the sporadic form of the disease in the affected individual. There 
appears to be a trend for genetic anticipation whereby, the disease occurs early or is 
more severe in the subsequent generations.15. 
UPDATED CLASSIFICATION OF PH 
Pulmonary hypertension (PH) is categorised into five groups:  
 group 1, PAH;  
 group 2, PH associated with left sided heart diseases;  
 group 3, PH associated with lung disease and/or hypoxaemia;  
 group 4,PH due to chronic thrombotic and/or embolic disease; and  
 
 
 group 5, miscellaneous 16  
PAH (group 1):  
This group comprises patients with pulmonary arterial hypertension. 
Idiopathic and heritable PAH  
IPAH is a disease characterized by sporadic occurrence, no family history of PAH 
and the absence of  risk factors for PH. In contrast, in familial PAH there are mutations 
of the bone morphogenetic protein receptor type 2 (BMPR2) gene in about 70% of 
cases.17   
Drug and toxin induced PAH 
Anorexigens like fenfluramine and dexfenfluramine are also a rare cause of PAH. 
But drug induced PAH is decreasing in incidence as these agents are banned now. 
Selective serotonin reuptake inhibitors have also been found to cause PAH after their 
use in pregnant women.  
PAH associated with connective tissue disease 
Connective tissue diseases, more specifically, systemic sclerosis and systemic lupus 
erythematosus (SLE) are a well known cause of PAH. Interstitial lung disease is also 
common in these diseases and add to the severity of PAH in these individuals. In 
patients with systemic sclerosis, the prevalence of PAH is up to 16%. The prognosis for 
these patients with PAH associated with systemic sclerosis is particularly poor, 
compared to those patients diagnosed with  systemic sclerosis who have no PAH. 18  
 
 
 
PAH associated with congenital heart disease 
Congenital heart disease has an incidence of 1% in the general population. Fifteen 
percent of these patients eventually develop PAH. 19 Eisenmenger’s syndrome is the 
most severe form of PAH in this group, as determined by the value of PVR,  and is 
characterized by reversal of the initial left to right shunt, limitation of exercise capacity 
and cyanosis. 
PAH associated with HIV infection 
Patients with HIV infection have a  prevalence of PAH of about 0.5%. 20 PAH is a 
well known complication of HIV infection. The highly active antiretroviral therapy has 
improved survival rates in patients infected by HIV. Hence nowadays the morbidity and 
the prognosis in patients with HIV infection is determined by  the other non-infectious 
complications of HIV infection like PAH. 
Portopulmonary hypertension 
Portal hypertension is rarely associated with the  development of PAH. This is 
known as porto pulmonary hypertension. The prevalence of PAH in patients with portal 
hypertension is 2 to 6%, as reported in a number of prospective studies. The presence 
and severity of cirrhosis of liver and the ventricular function determine the prognosis in 
such patients.21  
PH due to left heart disease (group 2) 
This category includes patients with PH due to left heart disease. Left ventricular 
myo-pericardial disease or left sided valvular heart disease cause increased left 
 
 
ventricular end-diastolic pressure. This in turn causes increase in pulmonary venous 
pressure and PCWP, with resultant increase in pressure in the pulmonary arteries. The 
PVR is mostly normal and the transpulmonary gradient is <12 mm Hg in the majority of 
the patients in this group. 
PH owing to lung disease and/or hypoxia (group 3) 
Group3 includes patients with PH resulting from lung disease or hypoxia 
(interstitial lung diseases, Chronic obstructive pulmonary disease, and chronic hypoxia 
as a result of prolonged stay in high altitudes). 
Chronic thromboembolic pulmonary hypertension (group 4) 
At 2 years after an index episode of pulmonary embolism, the incidence of 
symptomatic CTEPH is found to be about 3.8%, as reported from prospective studies. 
The major pathology in CTEPH is the presence of organized residual thrombus in the 
proximal branch pulmonary arteries and also the occurence of small vessel arteriopathy. 
The  pathology in the distal vessels in CTEPH is almost identical to that seen in PAH. 
Together , these lesions contribute to the progression of PH.22 
 PH with unclear etiologies (group 5) 
Group 5 comprises several disorders associated with PH for which the etiology is 
either unknown or involves multiple factors. Myeloproliferative disorders like 
polycythaemia vera, chronic myeloid leukaemia and  essential thrombocythaemia are 
listed in this group; metabolic disorders (Gaucher disease, type I glycogen storage 
disease, hypothyroidism, hyperthyroidism) and systemic disorders (sarcoidosis, 
 
 
lymphangioleiomyomatosis, neurofibromatosis, Langerhan’s cell histiocytosis) leading to 
PH are also included in this group. 
 
Table 3: ETIOPATHOGENESIS AND PATHOLOGY OF PULMONARY HYPERTENSION 
Suggested Mechanisms for Idiopathic Pulmonary Artery Hypertension 
 
Proposed Mechanism Evidence 
  
Early/sustained 
vasoconstriction 
Altered smooth muscle cell calcium kinetics 
Endothelial dysfunction 
   
Genetic predisposition 
  
Familial disease with gene locus identified 
Susceptibility with exposures, e.g., anorexigens, HIV, 
portal hypertension 
Pulmonary 
thrombosis/embolism 
Widespread occlusion of arteries/arterioles. Altered 
endothelial–platelet interaction 
Autoimmune disease Raynaud phenomenon and antinuclear antibodies 
common; female gender predilection 
 
 
Injury to the layers of the wall of the small muscular pulmonary arteries and the 
arterioles appears to be the common denominator in the pathogenesis of PH.23 The 
intima of these vessels proliferates, in response to injury, leading to the endothelium 
changing from a single flat layer to a piled-up form that narrows the vascular lumen. 
Moreover, the media and the adventitia of the affected vessels too undergo 
hypertrophy. 
 
 
The primary site of injury in IPAH remains unknown. An intrinsic defect in the 
function of the ion channel and in calcium homeostasis in the vascular smooth muscle 
has been proposed. The endothelial function is disturbed, leading to an altered 
production and handling of the  endothelium-derived vasoactive substances, including 
nitric oxide, endothelin, and prostacyclin. These coupled with altered platelet-
endothelial interactions predispose to intravascular thrombosis and release of growth 
factors, leading to an inexorable course of enhanced vascular reactivity, endothelial 
proliferation and remodeling  and obliterative vasculopathy.  
Many different etiologies lead to pulmonary hypertension. Ingestion of the 
anorexigens fenfluramine and dexfenfluramine have been demonstrated to markedly 
increase the risk of PAH; HIV infection also has been implicated; and  ingestion of toxic 
oil had also led an outbreak of pulmonary hypertension in Spain ;. 23 An epidemic of PAH 
broke in Europe between 1967 and 1970 and was linked to the use of aminorex, an 
anorectic agent; this also raised the prospect of hereditary predisposition, because only 
1 in 1000 persons who took the drug developed PH. Of late, the fenfluramines have also 
been associated with both severe PH and valvular heart disease.23  
In recent past, PAH has been genetically linked in an increasing number of 
patients.23 The hereditary pattern is autosomal dominant inheritance with incomplete 
penetrance. The gene responsible for the familial disease has been identified as the 
BMPR2 (bone morphogenetic protein receptor 2) gene, which is a member of the 
transforming growth factor- family. One important insight provided by the study of the 
 
 
families with familial   PH is the diversity of pulmonary vascular lesions in the members 
of the same family. 
The progressive reduction of the pulmonary arterial luminal cross sectional area 
gradually elevates PVR and leads to RV pressure overload, increased RV strain and RV 
failure. The small pulmonary arteries (40 and 100 µm diameter) and arterioles are the 
vessels which are mainly affected by the pathological process. The occlusive lesions 
affect more than one layer of the vasculature. Medial muscular hypertrophy 
predominates in some areas; in others, the intimal  proliferation is more dominant. 
Added to this,  evidence of inflammation may also be seen. 
Histologic examination of the lung shows a variety of pulmonary precapillary 
lesions that are consistent with the diagnosis of PAH : angiomatoid lesions, plexiform 
lesions, concentric intimal fibrosis and necrotizing arteritis. Recent thrombi in small 
pulmonary arteries and arterioles are found at autopsy in patients with IPAH, more so in 
patients in whom the RV has failed. Although similar thrombi may not have initiated PH 
in IPAH, nevertheless, they are complicating factors that aggravate and exaggerate PH. 
The pathological features of the PH groups. 
Group 1, PAH: In this group, the small distal pulmonary arteries are the site of the 
pathological lesions. These are : intimal proliferative and fibrotic changes, medial 
hypertrophy, adventitial thickening, complex lesions (plexiform, dilated lesions), 
perivascular inflammatory infiltrates, and thrombotic lesions. Pulmonary veins are 
characteristically not affected. 
 
 
Group 1’ : PVOD is the main condition grouped in this subgroup. The disease  involves 
the septal veins and pre-septal venules. The characteristic lesions are: muscularization 
of veins, occlusive fibrotic lesions, patchy capillary proliferation, alveolar haemorrhage, 
pulmonary oedema, inflammatory infiltrates, lymphatic dilatation and lymph node 
enlargement. Distal pulmonary arteries also demonstrate medial hypertrophy, intimal 
fibrosis, and uncommon complex lesions. 
Group 2, PH due to left heart disease: This group demonstrates the following 
pathological lesions: enlarged, thickened pulmonary veins, interstitial oedema, dilated 
pulmonary capillaries, alveolar haemorrhage, and lymphatic vessel and lymph node 
enlargement. Distal pulmonary arteries also show medial hypertrophy and intimal 
fibrosis.  
 
 
 
 
 
 
 
 
 
 
 
 
Potential pathobiological and pathogenetic mechanisms of PAH 
 
 
Group 3, PH due to lung diseases and/or hypoxia: Intimal proliferation of the small, 
distal pulmonary arteries and medial hypertrophy are the characteristic pathological 
changes seen in this group.  Also seen are fibrotic areas and  variable levels of reduction 
of the vascular luminal area in the  emphysematous lung. 
Group 4, CTEPH: Characteristic pathological lesions include organized thrombi adherent 
to the medial layer of the medium sized pulmonary arteries, which replace the normal 
intima, occlude the lumen to varying degrees or form webs and bands. A pulmonary 
arteriopathy identical to that of PAH is seen in the areas not containing the thrombi.  
Collateral vessels from the systemic circulation sometimes grow to reperfuse the areas 
downstream to the total obstructions. 
 
Vascular lesions in IPAH 
 
 
 
 
 
Group 5, PH with multifactorial mechanisms: There are no specific pathological 
changes that are unique to this group, which includes different conditions with different 
pathological lesions with  unclear or multifactorial causes. 
 
DIAGNOSIS OF PH 
The diagnosis of PH is usually made at an advanced stage of the disease. The 
natural course of the disease is characterized by progressive clinical worsening and 
reduced life expectancy. Screening for  the diagnosis of PH is commonly made by 
transthoracic echocardiography(TTE), and  the final confirmation of the disease is by 
right heart catheterisation.24 The diagnostic algorithm of PH involves a battery of tests 
to make the diagnosis and to place it in the appropriate clinical group and subtype of 
PH. However, the disease is not easy to diagnose. The predominant and common 
symptoms of PH are dyspnea and easy fatiguability; as the disease progresses, patients 
develop palpitations, chest pain, leg edema and ascites; syncope can also occur. A high 
level of suspicion is necessary diagnose PH. An usual delay of 2 to 3 years from the  
onset of symptoms to the  establishment of the diagnosis of PH is usual. 
Electrocardiogram 
The electrocardiogram (ECG) features seen in cases of  PH are: features of right 
ventricular hypertrophy: right axis deviation, persistent S wave upto V6 and R> S in V1. 
However, the  sensitivity and specificity of the ECG in the diagnosis of PH are very low 
and so ECG is not a useful screening  tool for diagnosing PH. However, there are a few  
 
 
ECG findings in patients with IPAH that are useful in predicting the prognosis: Over a 6 
year follow-up period, the P wave voltage in lead II of > 0.25 mV has been proven to 
predict a 2.8-fold increase in the  risk of mortality.19 
 
Echocardiography  
Echocardiography is an important screening tool in the diagnosis of PH. 
Transthoracic echocardiography (TTE) is useful for Doppler analysis. It is also helpful to 
establish the diagnosis of myocardial, valvular,  and congenital causes for PH. Moreover, 
the RV morphology can be determined. The 2-D echo findings in PH include: RV 
hypertrophy, enlarged right sided chambers and reduced global RV function as a 
consequence of chronic RV pressure overload due to increased PVR. 
 
 
 
 
 
 
 
 
 
 
Diagnostic algorithm for pulmonary hypertension. ABG, arterial blood gases; PAH, pulmonary arterial 
hypertension; PH, pulmonary hypertension; TOE, transoesophageal echocardiography; TTE, transthoracic 
echocardiography; *, required in specific circumstances 
 
 
 
In acute pulmonary embolism, the echocardiographic signs, like the McConnell 
sign (decreased wall motion in the mid RV free wall and normal wall motion of the apex 
of the RV),  the 60/60 sign (pulmonary Artery Acceleration Time [PAAT] < 60 ms and the 
tricuspid regurgitation peak gradient (TRPG) > 60 mmHg), and the RV overload criteria 
(at least one of: right-sided cardiac thrombus, systolic flattening of the interventricular 
septum, RV/LV ratio > 1, RV diastolic dimension in the parasternal view > 30 mm, PAAT < 
60 ms or the tricuspid regurgitation peak gradient (TRPG) > 30 mm Hg in the absence of 
RV hypertrophy), greatly increase the diagnostic utility of echocardiography to suspect 
the diagnosis. 
Echocardiography can both overestimate as well as underestimate the pulmonary 
pressures. This is mainly due to the overestimation of TRVmax  but can also be due to 
the overestimation of RAP. Older and obese patients can normally have PAPs that are 
higher than that in younger and normal weighing patients; a higher threshold of PAP 
must therefore be used in these patients to diagnose PH.  
Lung Scans 
Ventilation–perfusion scans are of value in the diagnosis and exclusion of 
pulmonary thromboembolic disease. 
Radionuclide Studies 
The response of the RV ejection fraction to exercise can be assessed using 
radionuclide angiography, which is of prognostic value. Scintigraphy using thallium-201 
has also been used in detecting hypertrophy of the RV caused by PH. 
 
 
Lung Biopsy 
The sampling of the lung tissue by either open thoracotomy or thoracoscopy is 
rarely helpful in finding the etiology of the PH. Moreover, the procedure carries a 
substantial risk in these hemodynamically compromised individuals. And attempts to 
predict responsiveness to vasodilators based on  lung biopsy have had  little success. 
CT / CT pulmonary angiography  
The etiological conditions that can be diagnosed by high resolution CT are: 
interstitial lung disease, connective tissue disease, CTEPH (mosaic pattern is seen 
indicating areas of hyperperfusion interspersed with areas of hypoperfusion), PVOD and 
PCH .  
Magnetic resonance (MR) imaging  
Assessment RV volumes, mass and function are reliably done using magnetic 
resonance (MR) imaging. MR angiography may in the future be the diagnostic test of 
choice in acute pulmonary embolism and CTEPH. MR imaging findings in PH includes: 
delayed hyperenhancement, changes of septal curvature, RV ejection fraction, and non-
invasively measured cardiac index.25  
Other tests 
6 min walking test , pulmonary function test and other laboratory tests including 
markers of autoimmune diseases like antinuclear antibodies (ANA), markers of 
coagulation disorders, screening for HIV and viral hepatitis, and (eg, protein S and C, 
lupus anticoagulants, von Willebrand factor)etc., should be done. Quantification of the 
 
 
levels of the cardiac biomarker brain natriuretic peptide (BNP, NT-proBNP) is of 
immense prognostic value and also useful in assessing the therapeutic efficacy of 
various drugs. 
Right heart catheterisation and vasoreactivity testing 
Echocardiography has its own limitations in assessment  of the pulmonary 
hemodynamics in patients with PH. For example, echo is not able to predict the 
transpulmonary blood flow and pulmonary venous pressure reliably. Right heart 
catheterization(RHC) is the gold standard for establishing the diagnosis of PH  and for 
vasoreactivity testing.25 
Hemodynamics predict the prognosis in PH. Obtaining the PCWP at rest and after 
vasodilator challenge is needed for the establishing the etiology of PH. Furthermore, 
another invaluable parameter derived is the transpulmonary gradient (MPAP - PCWP), 
which is increased in patients with PAH, but normal in those with PH resulting from left 
heart disease. An elevated PVR reflects an raised transpulmonary gradient and 
decreased cardiac output. 
Vasoreactivity testing using a short acting vasodilator is useful to assess the acute 
response of the pulmonary circulation and thus to select patients for high dose calcium 
channel blocker therapy.  
Although the gold standard for the definitive diagnosis of PH is invasively obtained 
pulmonary pressures got by RHC, precise noninvasive measurement of pulmonary 
 
 
arterial pressures is indispensible for diagnostic and prognostic purposes and to assess 
response to therapy. 
ROLE OF ECHOCARDIOGRAPHY IN PULMONARY HYPERTENSION 
Pulmonary hemodynamics are involved in many clinical situations, because of the 
close relationship between left-heart and right-heart hemodynamics, and also because 
the pulmonary vasculature is a target for all the diseases that damage the arteries. The 
study of pulmonary hemodynamics is of immense importance in many diseases which 
directly or indirectly involve the cardiopulmonary apparatus. A more accurate 
evaluation of pulmonary hemodynamics is valuable for the diagnosis and the prognosis 
of specific clinical diseases and also to validate new therapeutic approaches. 
The accurate estimation of PAP and PVR is a major step in the diagnosis, prognosis, 
the selection of appropriate therapy, and the follow-up of patients with PH. Though the 
gold-standard method for evaluating pulmonary hemodynamics is unquestionably 
invasive right-heart study, its use cannot be justified for many conditions.  
Ultrasound imaging has continuously evolved over the recent years, leading to the 
development of several new echocardiographic indices that allow the evaluation of 
pulmonary pressures (systolic, mean, and diastolic) and also the estimation of other 
pulmonary hemodynamic parameters, such as PVR, PCWP and the pulmonary 
capacitance and impedance. Thus, it is now possible to obtain a complete and accurate 
description of the pulmonary hemodynamics using noninvasive echo imaging26.  
 
 
Non-invasive assessment of systolic pulmonary artery pressure  is a routine 
investigation in all the echocardiographic laboratories. Doppler echocardiography  is 
recommended as the initial noninvasive modality of choice in the screening and 
evaluation of PH. Echocardiography is useful in evaluating the  right-sided chamber size 
and function and also the presence of pericardial effusion, which are known to impact 
survival in patients with PH. Pericardial effusion, septal displacement(which appears flat 
or bows towards the right ventricle because of a decreased interventricular pressure 
gradient when pulmonary pressure becomes near systemic) and right atrial enlargement 
are the three significant echocardiographic abnormalities that predict adverse outcomes 
in patients with severe IPAH. These characteristics help identify patients in whom more 
intensive medical therapy or earlier transplantation are warranted27.  
Many echocardiographic signs can be present in patients with PH, involving the 
right ventricle (hypertrophy, dilation, or reduction of systolic function). Though Doppler 
echocardiography has long been used to estimate systolic pulmonary artery pressure, 
because of its limited accuracy and reproducibility, invasive cardiac catheterization 
remains the gold standard for the accurate assessment of right heart hemodynamics28  
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
Many echocardiographic indexes have been proposed over the past few years, to 
improve, replace, or complete the standard basic echocardiographic evaluation of 
pulmonary hemodynamics28.  
Doppler echocardiography is helpful in the estimation of the RV systolic pressure. 
The pressure gradient between the RV and the right atrium is estimated using the 
modified Bernoulli equation, PG = 4v2, where v is the maximum velocity of the tricuspid 
regurgitant jet. An estimated right atrial pressure is then added to this value to obtain 
the right ventricular systolic pressure. This is equal to the pulmonary artery systolic 
pressure in the absence of pulmonary stenosis. Determination of PASP from the sum of 
the peak RV-RA gradient and the estimated RA pressure has been proved to be a reliable 
method since the publication by Yock and Popp29,30 in 1984 and has also been proven in 
other studies.31 Many investigators have repoted a strong correlation between the 
Doppler estimates of pulmonary artery pressures using this method and the invasively 
obtained measurements during right-heart catheterization. 
The major concern in the noninvasive evaluation of PASP (and of MPAP and 
PADP)since it is an important screening test, is to reduce false-negative results as much 
as possible (ie, to minimize error during the estimation of PASP). The underestimation of 
PASP with echocardiography is mostly due to the underestimation of RAP and of 
TRvmax. To minimize this error, TRv should be measured in multiple views, looking for 
the maximal TRvmax; color flow Doppler should be used to get the best alignment 
 
 
between the  regurgitant flow and the Doppler sample volume . Many studies have also 
shown that inadequate TRvmax signals can be enhanced with the use of                
contrast 32,33,34,35,36.  
 Although the application of this technique to estimate PASP has been widely 
validated, its precision is questionable: in studies that have compared the 
echocardiographically estimated values with the true values measured by right-heart 
catheterization, the mean difference ranged from 3 to 38 mm Hg. The PASP was 
underestimated by the echocardiographic method by >20 mm Hg in 31% of all patients 
studied18. In a more recent study, in 48% of 63 patients studied, echocardiography-
derived PASP differed by more than 10 mm Hg from the invasively measured PASP; the 
magnitude of PASP underestimation was found to be greater than that of its 
overestimation, particularly at higher PA pressures37.  The simplified Bernoulli equation 
may occasionally underestimate the RV-RA gradient because it neglects the inertial 
component of the complete Bernoulli equation38. In patients with severe TR, the 
Doppler envelope may be cut off because of the  early equalization of the RV and RA 
pressures, and in such situations, the simplified Bernoulli equation may underestimate 
the RV-RA gradient. TR signal is sometimes not sufficient to perform this measurement, 
as shown by a recent study that 25% of patients in a randomly selected cohort had 
insufficient TR for EPASP determination.  
For this reason, PASP evaluation with Doppler methods must not be used to 
decide when to treat patients or to monitor efficacy of therapy 24,25.   
 
 
Though the accuracy of Doppler PASP measurements has been questioned, thus 
limiting its utility as a diagnostic tool in asymptomatic PH,39  PASP estimation by TRvmax 
measurement remains the most feasible screening method in cases with suspected PH 
and also in patients with risk factors for the development of PH (family history, 
connective tissue diseases, HIV infection, portal hypertension, congenital heart diseases 
and chronic hemolytic anemia, as well as the use of drugs like fenfluramine derivatives, 
amphetamines, etc.). 16  TRvmax > 2.8 m/s (corresponding to a RA-RV peak pressure 
gradient > 31 mm Hg) is considered a reasonable cutoff value to define elevated 
pulmonary artery pressures, except in the elderly and in very obese patients, in whom 
physiologic PASP tends to be more elevated40.   
The European guidelines for the diagnosis and the treatment of PH consider 
echocardiographic diagnosis of PH to be ‘‘likely’’ when TRvmax is >3.4 m/s (or PASP is 
>50 mm Hg) and to be ‘‘possible’’ when TRvmax is between 2.9 and 3.4 m/s (or PASP is 
between 37 and 50 mm Hg), with or without other echocardiographic signs suggestive 
of PH, or when TRvmax  is >2.8 m/s (or sPAP is >36 mm Hg) with other findings 
suggestive of PH (RV hypertrophy or dilatation, increased pulmonary regurgitant 
velocity [PRv], etc).  
Though TTE estimates of PASP are derived from the maximal velocity of the 
tricuspid regurgitation  jet by convention, sometimes, there is insufficient TR to derive 
the estimated peak systolic pulmonary artery pressure in quite a number of patients. 
 
 
Though contrast agents can be used to enhance the tricuspid regurgitation signal, this 
requires venous catheterization.  
Other less invasive echocardiographic methods are therefore required to estimate 
the PASP. To date, in the absence of tricuspid regurgitation, no other noninvasive 
method of estimating the  PASP has been developed. 
Alternative TTE methods for pulmonary artery pressure estimation have been 
evaluated. These include the measurement of blood flow through an anatomic defect 
(patent ductus arteriosus, ventricular septal defect,  or aortopulmonary shunt), 
measurement of the peak systolic and the end-diastolic pulmonary valve regurgitant 
velocity, and the measurement of the pulmonary artery acceleration time(PAAT) .   
The application of the simplified Bernoulli equation to the end-diastolic PRv is 
useful in the calculation of the pressure gradient between the right ventricle and the 
pulmonary artery in end-diastole; this value added to RAP estimates PADP, with a strong 
correlation with invasive PADP measurements41 Recently Ristow et al42 demonstrated 
that when the end-diastolic pulmonary regurgitant gradient is >5 mmHg ,it predicts 
cardiac dysfunction, particularly in patients with poor functional status, elevated serum 
B-type natriuretic peptide, elevated LV mass index, and in those with systolic and 
diastolic dysfunction. As in cases with tricuspid regurgitation, weak pulmonary 
regurgitant Doppler signals may be enhanced with the use of contrast.43,44  
The PRv pattern, when present,  is characterized by a rapid rise in the flow velocity 
immediately after closure of pulmonary valve and a gradual deceleration until the 
 
 
pulmonary valve opening in the next cardiac cycle (end-diastolic PRv). Masuyama et al45 
showed that the application of the Bernoulli equation to the peak PRv shall provide a 
reasonable estimate of MPAP. More recently, Abbas et al46 has also validated this 
method in another study and showed that adding RAP improves the accuracy of the 
MPAP estimate. 
Aduen et al 47 proposed a new, simple method to estimate MPAP by the addition 
of the estimated RAP to the RV-RA mean systolic gradient obtained by tracing the TRv 
profile. This method was validated in 102 patients. It was compared with simultaneous 
right-heart catheterization derived values; it showed great reliability and accuracy in 
diagnosing PH. This method appears very simple and also can easily be incorporated 
into a standard echocardiographic examination protocol, allowing a reliable estimation 
of MPAP. 
RV isovolumic relaxation time (RVIRT) and tissue Doppler–derived RVIRT have also 
been studied to examine their usefulness in estimating the  systolic pulmonary artery 
pressure (PASP). Brechot et al.48 had studied 26 patients by echocardiography and 
cardiac catheterization. Doppler-derived RVIRT correlated strongly with PASP and it was 
possible to reliably exclude PH. But, prolonged RVIRT is not specific for PH, and RVIRT-
derived PASP did not agree well with the invasively-derived value.49  
An accurate estimation of the RAP is of immense importance to obtain accurate 
noninvasive evaluations of pulmonary artery pressures. Because RAP is strongly 
correlated with central venous pressure,50 the most widely used method for its 
 
 
estimation is the observation of the diameter and also the collapsibility of the inferior 
vena cava.51 The IVC is examined in the subcostal view; the patient should be in supine 
position, because IVC size is significantly smaller in the left lateral position and 
significantly larger in the right lateral position.52 IVC diameter is measured within 2 cm 
of the RA – IVC junction at end-expiration and end-diastole53 and during a ‘‘sniff’’ 
maneuver; the decrease of its diameter with the sniff maneuver is a measure of IVC 
collapsibility.51 The IVC can be dilated (>2 cm) in younger patients despite normal 
RAPs52,54; IVC size is also considered with caution in patients who are on mechanical 
ventilation. 
Under normal conditions, the Doppler pulmonary flow velocity curve has a 
domelike contour; the maximum velocity is in the middle of systole. In PH, it is more 
triangular in contour; the  peak velocity is in early systole; in some cases a slower rise 
during deceleration can also be observed, resulting in mid systolic notching. 
PH in humans is thus characterized by a shortening of the pulmonary artery 
acceleration time (PAAT) as measured by Doppler echocardiography; as the pulmonary 
artery pressure increases, the pulmonary acceleration time shortens. Increase in heart 
rate is also known to reduce the PAAT. It has been demonstrated that increase in heart 
rate shortens pulmonary artery  acceleration time only at lower MPAP, but have little 
effect on PAAT at higher (> 25 mm Hg)MPAP55.  
The pulmonary artery acceleration time (PAAT), is defined as the time interval 
from the onset of forward flow in the pulmonary artery to the peak velocity of this flow; 
 
 
this  has been shown to be inversely related to PASP and MPAP.  In a study by Lanzarini 
et al,56 a PAAT< 93 ms identified 67.4% of patients with PH. In combination with other 
indexes of pulmonary  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pulsed-wave Doppler interrogation of the pulmonary artery. RVET is measured from the onset 
of RV ejection to that of zero flow. PAAT is the interval from the onset of RV ejection to peak 
flow velocity (asterisk). 
 
 
 
 
 
 
pressures, PAAT can be a very powerful tool in the  diagnosis of PH. 
THE MPAP may be estimated by using PAAT measured by pulsed Doppler of the 
pulmonary artery in systole; MPAP = 79 - (0.45x PAAT). In patients with PAATs < 120 ms, 
the formula for MPAP is 90 - (0.62 x PAAT) performs better. Generally, the shorter the 
AT, the higher the PVR and hence the PA pressure, when the heart rate is in the normal 
range of 60 to 100 beats/mins.30,57 
In 1983 , Kitabatake et al. [20] studied a series of 33 patients, of whom 16 had a 
MPAP higher than 20 mmHg by Doppler echocardiography. In the patients with a 
normal PAP, ejection flow velocity reached peak at mid-systole, producing a dome-like 
Doppler pulmonary flow velocity curves in a patient without pulmonary hypertension (Type I) and in two 
patients with pulmonary hypertension (Types II and III). Type I: normal, dome-like contour with a maximum 
velocity in the middle of systole. Type II: triangular contour, with a sharp peak in early systole, and a 
decreased acceleration time. Type III: similar to Type II, but with a mid-systolic notching. 
 
 
contour; in the patients with PH, the time to peak flow velocity (PAAT) reduced, 
producing a triangular contour. In 10 patients, a slower secondary rise was observed 
during deceleration , resulting in mid-systolic notching . Satisfactory Doppler recordings 
could be obtained in 70% of patients examined in the catheterization laboratory. This 
increased to 90% in patients with PH. The study also showed a significant correlation 
between pulmonary valve motion and the pulmonary artery flow velocity pattern; but it 
was noted that mid-systolic notching is not always related to the severity of PH, and can 
be intermittent. 
Kitabatake et al.58 showed that PAAT correlates well with MPAP and its logarithm 
as determined by cardiac catheterization. They further showed that PAAT corrected for 
RVET time, a method of adjusting for heart rate, slightly strengthened the correlation 
between PAAT and MPAP. In a subsequent study, Dabestani et al. described the same 
relationship as one that observed the following equation: MPAP = 73 - (0.42 x PAAT). In 
contrast to Kitabatake et al., they found that neither the logarithmic transformation of 
MPAP nor the correction for RVET improved the accuracy of estimating the MPAP using 
PAAT. Together, these studies established the capacity of Doppler derived 
measurements of PAAT to provide accurate estimates of MPAP. In addition, PAAT in the 
RV outflow tract, unlike estimates using tricuspid regurgitation velocity, is available in 
virtually all patients.58  
Pulmonary artery acceleration time measurement, previously thus shown to 
correlate well with invasively measured MPAP, is an useful alternative to the tricuspid 
 
 
regurgitation Vmax-dependent method; it does not rely on the presence of an anatomic 
defect or valvular regurgitation; it is measurable in most of the individuals. Currently, 
measurement of PAAT cannot be used as an alternative to TRVmax for the derivation of 
EPASP, because the relationship between these two parameters has not been validated. 
Despite many important publications, the use of PAAT in clinical practice has so far 
remained relatively limited. This is because the majority of the publications reporting 
echocardiographic PAP  estimates have relied on TR Vmax-derived EPASP.   
Most clinicians who rely on TTE for PAP quantification have developed a familiarity 
with and a preference for peak systolic, and not the mean, pulmonary artery pressure 
values. Despite the well-established role of invasively measured MPAP values in the 
diagnosis and management of PH, the use of noninvasively derived EPASP values is also 
justifiable, given their accuracy, reproducibility, and extensive validation.18  
The relationship between different components of pulmonary artery pressure 
(SPAP, MPAP, and PADP) has been shown to remain constant after changes in posture 
and activity,59 which implies that any of the three can be used as a surrogate of the 
other two. Accurate and precise estimates of MPAP may be obtained by using PASP. The 
single-pressure model formula, mPAP = 0.61 × PASP + 2 mm Hg, was most accurate, in a 
recent study by Chemla et al.60  
Although many useful methods of assessing MPAP have been developed, there 
currently exists no method that can be used to derive an EPASP value in the absence of 
TR. In a recent series, a significant number of patients with pulmonary artery pressures 
 
 
>50 mm Hg had mild TR or less, rendering the reliance on TRVmax for the measurement 
of EPASP unfeasible.61 Although saline injection is useful to augment a weak or 
immeasurable TRsignal,62. this approach involves the insertion of an intravenous line 
and coordinated injection of agitated saline and simultaneous color Doppler 
interrogation of the tricuspid valve. Although this technique may be useful, it is resource 
and time consuming and thus may not be optimal in a busy echocardiography 
laboratory. This underscores the need for a method to pulmonary artery pressure 
assessment that is not dependent on the presence of TR and thus justifies the use of a 
PAAT derived method in the echocardiography laboratory. 
Yared et al63 observed a strong, inverse correlation between PAAT and EPASP 
among a cohort of patients with a wide range of EPASP values. Quantification of this 
relationship by linear regression led to the derivation of an equation by which PAAT 
could be used to provide EPASP values comparable with those obtained by using 
TRVmax.  
This TR-independent approach using PAAT for the quantitative assessment of 
EPASP performed well across a wide range of pulmonary artery pressures. The use of 
PAAT thus, for the derivation of EPASP increases the overall percentage of patients in 
whom noninvasive assessment of pulmonary hemodynamics can be performed. PAAT 
was found to be easily obtainable and also strongly correlated with TRVmax.  
However, an important limitation of this study was that it was  a comparison of 
measurements derived from only the echocardiograms of patients, without correlative 
 
 
invasive hemodynamic measurements, which is the gold standard. Confirmation of the 
findings using invasive measurement of peak systolic pressure is important. 
In our study, we aimed to overcome this limitation and to correlate the PASP and 
the MPAP obtained by invasive right heart pressure study, with the measurements 
obtained non invasively by Doppler echocardiography derived PAAT and also the EPASP  
derived from TRVmax. We examined the relationship between pulmonary artery 
acceleration time and both tricuspid regurgitation Vmax and estimated peak systolic 
and mean pulmonary artery pressure. We also evaluated the accuracy of Doppler 
echocardiography in estimating pulmonary artery systolic and mean pressures, by 
measuring pulmonary artery acceleration time and tricuspid regurgitation Vmax, and 
comparing it with invasively determined right heart pressures in patients referred to our 
department for evaluation or treatment of pulmonary hypertension , in whom right 
heart catheterization for pressure study was clinically indicated.  Doppler 
echocardiography was performed within one hour of hemodynamic assessment by 
right-heart catheterization. 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
The aim of the study was  
1. To estimate the pulmonary artery systolic pressure by measuring the tricuspid 
regurgitation peak gradient by Doppler echocardiography in patients with pulmonary 
hypertension and compare it with invasively derived pulmonary artery systolic pressure 
obtained by right heart catheterization. 
2. To estimate the mean pulmonary artery pressure from pulmonary artery acceleration 
time measured by Doppler echocardiography in patients with pulmonary hypertension 
and compare it with invasively derived mean pulmonary artery pressure obtained by 
right heart catheterization. 
3. To find which of the above two methods is more accurate in  deriving the pulmonary 
artery pressures. 
4. To test the hypothesis that the pulse Doppler echo derived pulmonary artery 
acceleration time strongly correlates with invasive pulmonary artery systolic pressure. 
5. To compare  the strength of correlation   between pulmonary artery acceleration time 
and  
a. invasive pulmonary artery systolic pressure  
b. invasive mean pulmonary artery  pressure  
6. To compare  the strength of correlation   between invasively derived pulmonary artery 
systolic pressure and 
a. TRPG derived EPASP 
b. PAAT   
 
 
MATERIALS & METHODS 
Study Population:  
The study was conducted in patients referred to the Department of Cardiology, 
Govt. Rajaji hospital, Madurai for cardiac evaluation, in whom pulmonary hypertension 
was diagnosed based on transthoracic echocardiography and right heart catheterization 
was clinically indicated. Fifty three patients, twenty males and thirty three females, with 
a diagnosis of pulmonary hypertension established by transthoracic echocardiography, 
in whom right heart catheterization was clinically indicated  were studied. The clinical 
indication for catheterization was primary pulmonary hypertension in 5 patients, mitral 
valve disease in 19,  congenital heart disease with shunt lesion in 19, chronic pulmonary 
thrombo embolic pulmonary hypertension in 3, connective tissue disorder in 4, lung 
disease in 2 and other conditions in 1. Forty patients had clinical evidence of pulmonary 
hypertension, 8 had clinical tricuspid regurgitation and none had clinical pulmonary 
regurgitation. Fifty patients were in sinus rhythm and three in atrial fibrillation. 
Inclusion Criteria:  
Patients with pulmonary hypertension of various etiologies were included in the 
study. 
Exclusion Criteria: 
1. Paediatric age group patients were excluded 
2. Patients undergoing simultaneous left heart catheterization were not included. 
3. Patients with poor echo window were not included. 
 
 
4. Critically ill patients were also excluded. 
The instituitional ethical committee approval was obtained and all the patients 
selected for the study gave informed consent to undergo evaluation. 
Methods 
All the patients included in the study were subjected to detailed history taking and 
thorough and complete physical examination. Complete blood count, blood sugar and 
renal function test  were done in all patients. A 12 lead electrocardiogram and a chest X-
ray were obtained in all patients. They were also evaluated for the etiology of 
pulmonary hypertension by appropriate tests as indicated: anti nuclear antibody profile, 
coagulation profile, HIV testing, high resolution CT scan of the chest, ultrasound 
abdomen and pulmonary function testing. 
Echocardiographic evaluation 
All the patients underwent a detailed transthoracic echocardiographic evaluation 
using a standard protocol, within one hour of undergoing the right heart catheterization 
study. Two dimensional, M-mode , colour flow, spectral Doppler and tissue Doppler 
examinations were done using Philips IE-33 echocardiography machine. ECG monitoring 
was done during the examination. Examination was done in the left lateral decubitus 
and in the supine positions. 
To assess RV size, function and area, a complete set of standardized views were 
obtained. These included PLAX, parasternal RV inflow, PSAX, apical 4-chamber, right 
ventricle–focused apical 4-chamber , and subcostal views. 
 
 
The basal diameter, defined as the maximal short-axis dimension in the basal one 
third of the right ventricle was measured  on the RV focused apical  4-chamber view. 
Measurement of right ventricular outflow tract (RVOT) dimensions were made at 
the proximal or subvalvular level (RVOT-Prox) and at the distal or pulmonic valve (RVOT-
Distal) levels in the  parasternal long-axis RVOT anterior portion view,  basal parasternal 
short-axis view, and  parasternal short-axis of pulmonary bifurcation view. 
Measurement of end-diastolic right ventricular wall thickness was made in the 
subcostal 4 chamber view. 
RVSP and therefore the EPASP was determined from the peak TR jet velocity, using 
the simplified Bernoulli equation and this value was combined with an estimate of the 
RA pressure: EPASP = 4(V)2 + RA pressure, where V is the peak velocity (in meters per 
second) of the tricuspid valve regurgitant jet . TR signals were obtained from several 
windows and the signal with the highest velocity was used. Doppler sweep speed of 100 
mm/s was used for all tracings.  
RA pressure was estimated by IVC diameter and the presence of inspiratory 
collapse. The subcostal view was used for imaging the IVC, with the IVC viewed in its 
long axis. The measurement of the IVC diameter was made at end-expiration and just 
proximal to the junction of the hepatic veins with the IVC. To  assess IVC collapse, the 
change in diameter of the IVC with  sniff and also with quiet respiration were measured, 
ensuring that the change in diameter did not reflect a translation of the IVC into another 
plane. 
 
 
Table 4: Estimation of RA pressure on the basis of IVC diameter and collapse 
Variable Normal (0-5 [3] 
mm Hg) 
Intermediate (5-10 [8] mm Hg) High (15 
mm Hg) 
IVC 
diameter 
≤ 2.1 cm ≤ 2.1 cm ≥2.1 cm ≥2.1 cm 
Collapse 
with sniff 
> 50% < 50% >50% <50% 
 
PADP was estimated from the velocity of the end-diastolic pulmonary regurgitant 
jet using the modified Bernoulli equation: [PADP = 4 x (end-diastolic pulmonary 
regurgitant velocity)2 + RA pressure]. 
Pulsed-wave and continuous-wave Doppler interrogation of the proximal 
pulmonary artery was  performed in the parasternal short-axis view with the sample 
volume placed along the long axis of the main pulmonary artery to maximally align 
blood flow and Doppler interrogation. This view was also used to exclude pulmonary 
stenosis. Using the pulse-wave Doppler profile, PAAT, RVET, and heart rate were 
measured. PAAT was defined as the interval between the onset of systolic pulmonary 
arterial flow and peak flow velocity . RVET was defined as the interval between the 
onset of RV ejection to the point of systolic pulmonary arterial flow cessation. All values 
used for the analysis were the average of three consecutive cardiac cycles, but in  
patients with atrial fibrillation, five-beat averages were obtained. Mean PA pressure was 
estimated from PAAT measured by pulsed Doppler of the pulmonary artery in systole: 
Mean PA pressure = 90 - (0.62 x AT) {Mahn & Dabestani formula}. 
 
 
 
 
The percentage RV fractional area change, FAC, which is a measure of RV systolic 
function, and defined as (end-diastolic area - end-systolic area)/end-diastolic area  x 100 
was obtained by tracing the RV endocardium both in systole and diastole from the 
annulus, along the free wall to the apex, and then back to the annulus, along the 
interventricular septum. 
Tricuspid annular plane systolic excursion (TAPSE) was  acquired by placing an M-
mode cursor through the tricuspid annulus and measuring the amount of longitudinal 
motion of the annulus at peak systole in the apical 4 chamber view. 
Table 5: Abnormal Values 
RV basal diameter cm  >4.2 
RV subcostal wall thickness  mm >5 
RVOT PSAX distal diameter   cm >2.7 
RVOT PLAX proximal diameter cm  >3.3 
TAPSE cm <1.6 
Pulsed Doppler peak velocity at the annulus(Tric s’)cm/s  <10 
FAC (%)  <35 
E/A ratio  <0.8 or >2.1 
E/e’ratio  >6 
Deceleration time   ms  <120 
 
 
RV s’ or systolic excursion velocity was measured in the apical 4-chamber window, 
with a tissue Doppler mode region of interest highlighting the RV free wall. The pulsed 
Doppler sample volume was placed in either the tricuspid annulus or the middle of the 
basal segment of the RV free wall.  The velocity RV s’ was measured as the highest 
systolic velocity, without over-gaining the Doppler envelope. 
The parameters used to assess RV diastolic function namely, the  Doppler 
velocities of the transtricuspid flow (E, A, and E/A), tissue Doppler velocities of the 
tricuspid annulus (e’, a’, E/e’) and the E- deceleration time were measured in the apical 
4 chamber view. 
GRADING OF RV DIASTOLIC DYSFUNCTION. : A tricuspid E/A ratio < 0.8 impies impaired 
relaxation, a tricuspid E/A ratio of 0.8 to 2.1 with an E/e’ ratio > 6  impies  pseudonormal 
filling, and  a tricuspid E/A ratio > 2.1 with deceleration time < 120 ms implies restrictive 
filling. 
Right heart Catheterisation 
Right heart catheterization was performed after overnight fasting, at rest in the 
cardiac catheterization laboratory using the TOSHIBA machine, without sedation by the 
standard technique.  Catheterisation was done under local anaesthesia, through the 
right femoral venous route. Multipurpose catheter was used for pressure 
measurements. Pressure measurements were taken from the pulmonary arterial wedge 
position,  main pulmonary artery , right ventricle and right atrium at the end of 
expiration. 
 
 
Statistical Tools  
The information collected regarding all the selected cases were recorded in a 
Master Chart. Data analysis was done with the help of computer using Epidemiological 
Information Package (EPI 2010) developed by Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard deviations, 
chi square and  'p'  values were calculated. Kruskul Wallis chi-square  test was used to 
test the significance of difference between quantitative variables and Yate’s chi square 
test for qualitative variables. A 'p' value less than 0.05 is taken to denote significant 
relationship. Correlation coefficients were calculated using Excel software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Among this study population, pulsed-wave Doppler imaging of the main 
pulmonary artery was sufficient to measure PAAT in all the patients (53 of 53) studied. 
In contrast, 9.4% (5 of 53) did not have sufficient TR to measure TRVmax and only 43.4% 
of patients(23 of 53) had sufficient PR to measure PR end diastolic velocity. 
Totally, 53 patients were included in the study. Of this , 20 (37.7%) were males and 
33(62.3%) were females. The mean age of the patients was 33.7 ± 14.7 years. The age 
distribution of the patients studied was as in Table 1. Paediatric age group was not 
included in the study. 
Table 6: Age distribution 
Age group Cases 
No % 
Below 20 years 11 20.8 
20-29 years 13 24.5 
30-39 years 10 18.9 
40-49 years 11 20.8 
50 years & above 8 15.1 
Total 53 100 
Range 13 - 65 years 
Mean ± SD 33.7 ± 14.7 years 
 
 
 
Table 7: Symptoms 
Symptoms Yes No 
No % No % 
Chest pain 19 35.8 34 64.2 
Shortness of breath 47 88.7 6 11.3 
RV failure symptoms 2 3.8 51 96.2 
 
The most common presenting symptom was shortness of breath, which was 
present in 47(88.7%) of the patients studied. Symptoms of right ventricular failure was 
present only in two (3.8%) of the patients studied. Seven(35%) of the males and none of 
the females studied were smokers. The pulse rate of the patients studied ranged from 
64 to 112 beats per minute, with a mean of 82.3± 12.6. 
 
 
 
 
 
 
 
 
Table 8: ECG Findings 
ECG  results Cases 
No. % 
AF 3 5.7 
RVH 19 35.8 
RBBB 9 17.0 
BVH 3 5.7 
 
Two of the 53 patients studied were in atrial fibrillation and the rest were in sinus 
rhythm. ECG evidence of right ventricular hypertrophy was present in 19(35.8%) of the 
patients studied; RBBB was present in 9 (17.0%) patients, all of them with large ASD 
with pulmonary hypertension. 
 
 
 
 
 
 
 
 
 
Table 9: Groups of PH 
 
 
Group 
 
Clinical Diagnosis 
 
Cases 
  
 
No. % 
 
 
1 
CHD 19 35.8 
Cor AVF 1 1.9 
PPH 5 9.4 
SScl 4 7.5 
2 RHD 19 35.8 
 
3  
Cystic lung 1 1.9 
ILD 1 1.9 
4 CPTE 3 5.7 
All Total 53 100.0 
 
54% (29 of 53) of our patients belonged to group 1 pulmonary hypertension. Of 
them, 35.8%(19 of 53) had shunt lesion as the cause of PAH, 1 patient due to a coronary 
AV fistula, 7.5%(4 of 53) had systemic sclerosis and 9.4% (5 of 53) had idiopathic PAH. 
Group 2 PH due to left heart disease was present in 35.8% (19 of 53). Group 3 PH due to 
lung disease was present in 3.8%(2 0f 53) and group 4 due to  (3 of 53). 
 
 
 
 
 
Table 10 :TTE derived Pulmonary Hemodynamics 
 
Parameter Range Mean ± S.D. 
Tricuspid regurgitation Peak gradient 32 – 101 66.2 ± 23.2 
Estimated Right Atrial Pressure 3 – 15 5.36 ± 1.64 
Estimated Systolic Pulmonary Artery Pressure 37 – 106 71.7 ± 23.9 
Pulmonary Artery Acceleration Time 57 – 101 76.8 ± 13.8 
Right Ventricle Ejection time 239 – 295 267 ± 19.4 
PAAT / RVET ratio 0.2 – 0.41 0.29 ± 0.07 
PR derived PA Diastolic Pressure 10 – 37 24.8 ± 8.1 
Estimated mean Pulmonary Artery Pressure 27.8 – 54.6 42.6 ± 8.6 
 
The mean value of the tricuspid regurgitation peak gradient(TRPG) was 66.2 ± 23.2 
and that of the estimated Systolic Pulmonary Artery Pressure(ESPAP) was 71.7 ± 23.9 
Thus most of our patients had severe PH. 
The mean Pulmonary Artery Acceleration Time was 76.8 ± 13.8 and the calculated 
mean pulmonary artery pressure was 42.6 ± 8.6 
 
 
Table 11: Right Ventricle Dimensions 
Right Ventricle Diameter Range Mean ± S.D. 
Basal (cm) 2.1 – 4.3 3.52 ± 0.41 
RV outflow Tract – Proximal ( cm) 2.3 – 4.1 3.09 ± 0.5 
RV outflow Tract – Distal (cm) 2 – 4 2.79 ± 0.48 
RV free wall thickness (mm) 5 - 9 6.5 ± 1.0 
 
The mean basal RV diameter was 3.52 ± 0.41 (Normal <4.2cm). The mean proximal 
RVOT diameter in PLAX view was 3.09 ± 0.5 (Normal <3.3cm).  The mean distal RVOT 
diameter in PSAX view was 2.79 ± 0.48 (Normal <2.7cm) and the mean RV free wall 
thickness in subcostal view was 6.5 ± 1.0 (normal <5mm). Only the mean RVOT distal 
diameter was found to be above normal. 
 
 
 
 
 
 
 
 
 
Table  12: RV dimensions: Normal and abnormal 
Parameter(abnormal) 
 
Normal Abnormal 
No. % No. % 
RV basal diameter cm (>4.2cm) 52 98.1 1 1.9 
RV free wall thickness  (>5mm) 5 9.4 48 90.6 
RVOT PSAX distal diameter  
(>2.7 cm) 22 41.5 31 
58.5 
RVOT PLAX proximal diameter 
(>3.3 cm) 35 66 18 
34 
 
Table 13: Right Ventricular Systolic Function 
 
Parameter 
 
Range 
 
Mean± S.D. 
Cases 
Normal Abnormal 
No. % No. % 
Tricuspid annular plane 
systolic excursion(TAPSE) 
Normal – 1.6 to 3.0 
0.9 – 3.0 2.1±0.59 44 83.0 9 17.0 
Tricuspid annular Tissue 
Doppler velocity(Tric s’) 
Normal – 10 to 19 
6.1 – 20 13.47±3.17 49 92.5 4 7.5 
Fractional area change 
Normal > 35%  
22 - 60 46.2 ± 9.9 45 84.9 8 15.1 
 
 
The RV systolic function as measured by TAPSE was normal in 83% (44 of 53) of the 
patients. Tricuspid s’ was normal in 92.5% (49 0f 53) of the patients. The RV fractional 
area change was normal in 84.9% (45 of 53) of the patients. Overall, 17% ( 9 of 53) of 
the patients had RV systolic dysfunction. 
Table 14: Right Ventricular Diastolic Function 
 
 
 
 
 
 
 
 
The RV diastolic function was normal in 32.1% (17 of 53) patients. Impaired 
relaxation was present in 17% (9 of 53) patients. 50.9 % (27 of 53) patients had 
pseudonormal filling pattern and restrictive filling pattern was present in none of the 
patients studied. 
 
 
 
 
 
Diastolic Function 
Cases 
No. % 
Normal 17 
32.1 
Impaired relaxation 9 
17.0 
Pseudo normal filling 27 
50.9 
 
 
Table 15: Invasively obtained Right heart Pressures 
 
Invasive Pressures 
 
Range 
 
Mean ± S.D. 
PC Wedge Pressure 8 – 32 14.0 ± 7.33 
P.A. Systolic Pressure 38 – 108 70.0 ± 21.54 
P.A.Diastolic Pressure 17 – 43 27.96 ± 7.49 
Mean Pulmonary Artery 
Pressure 
28 – 58  42.34 ± 8.86 
RV Systolic Pressure 40 – 104 71.1 ± 21.4 
RV end Diastolic Pressure 3 – 15 9.42 ± 2.53 
Right Atrial Pressure 4 - 18 8.81 ± 2.52 
 
The mean value of the PASP measured by right heart catheterization was 70.0 ± 
21.54 ( Vs  the echo – Doppler estimated PASP of 71.7 ± 23.9) in the study population , 
that of PADP was 27.96 ± 7.49 (Vs echo derived mean value of 24.8 ± 8.1) and the mean 
pulmonary artery pressure was  42.34 ± 8.86( Vs the echo PAAT derived mean value of 
42.6 ± 8.6). The mean right  atrial pressure measured invasively had a mean value of 
8.81 ± 2.52(Vs echo derived value of 5.36 ± 1.64). 
  
 
 
Table16: Classification according to severity of PH 
 
 
 
 
 
 
 
 
The pulmonary hypertension was mild in 28.3%, moderate in 37.7% and severe in 
34% f the cases. 
Correlation between Echo derived findings and Invasively derived  findings 
There was strong inverse correlation between the echo measured PAAT and both 
the invasively measured PASP and the MPAP. This correlation was stronger for MPAP. 
This strong inverse correlation remained thus even after correction for heart rate  (i-e) 
between PAAT/RVET and the invasively measured PASP and the MPAP. This correlation 
was comparable to that between echo TRVmax derived EPASP and invasively measured 
PASP. Our study also showed strong direct correlation between echo derived PADP and 
the invasively measured PADP. 
 
 
Severity of PH (PASP mm Hg) 
Cases 
No. % 
Mild (38 to 50) 15 28.3  
Moderate (50 to 75) 20 37.7 
Severe( > 75) 18 34 
 
 
Table 17: Correlation between Echo derived findings and Invasively derived  
findings 
 
 
Correlation between 
 
 
Mean ±SD 
 
Correlation 
Coefficient 
 
Correlation 
Echo derived PAAT  76.8 ± 13.8  
-0.89 
 
Strong inverse Correlation Invasive PSAP 70.0 ± 21.54 
Echo derived PAAT  76.8 ± 13.8  
-0.93 
 
Strong inverse Correlation Invasive MPAP 42.34 ± 8.86 
Echo derived PAAT/RVET  0.29 ± 0.07  
-0.89 
 
Strong inverse Correlation Invasive PSAP 70.0 ± 21.54 
Echo derived PAAT/RVET   0.29 ± 0.07  
-0.90 
 
Strong inverse Correlation Invasive MPAP 42.34 ± 8.86 
Echo TRVmax derived ESPAP 71.7 ± 23.9  
0.95 
 
Strong direct  Correlation Invasive PSAP 70.0 ± 21.54 
Echo derived PADP  24.8 ± 8.1  
0.94 
 
Strong direct  Correlation Invasive PADP 27.96 ± 7.49 
The numbers marked in bold show positive correlation( >+ 0.5 or < - 0.5) 
 
 
 
Table 18: Correlation between Echo derived findings and Invasively obtained  findings 
in different groups of PH 
Correlated parameters Group 1 PAH Group 2 
Left heart 
disease 
Group 4 
CTEPH 
Echo based PAAT & Invasive PSAP -0.85 -0.86 -1.0 
Echo based PAAT & Invasive MPAP -0.86 -0.98 -1.0 
Echo based PAAT/RVET & Invasive PSAP -0.84 -0.85 -1.0 
Echo based PAAT/RVET & Invasive MPAP -0.83 -0.94 -1.0 
Echo based ESPAP & Invasive PSAP 0.95 0.92 1.0 
Echo based PREDP & Invasive PADP 0.95 0.65 - 
 The numbers marked in bold show positive correlation( >+ 0.5 or < - 0.5) 
The strength of correlation between PAAT and PASP and between PAAT and MPAP 
was strong among the different groups of PH, and this  was also not affected by 
correction for heart rate and was comparable to the strength of correlation between 
EPASP and invasively measured PASP.  
 
 
 
 
Table19 : Correlation between Echo derived findings and Invasively obtained  findings 
in different degrees of PH 
Correlation between Correlation Coefficient 
Mild PH Moderate PH Severe PH 
Echo based PAAT & Invasive PASP -0.81 -0.78 -0.09 
Echo based PAAT & Invasive MPAP -0.90 -0.91 -0.67 
Echo based PAAT/RVET & Invasive PASP -0.79 -0.83 -0.10 
Echo based PAAT/RVET & Invasive MPAP -0.84 -0.78 -0.50 
Echo based ESPAP & Invasive PASP 0.40 0.77 0.54 
Echo based PADP & Invasive PADP 0.46 0.93 0.93 
The numbers marked in bold show positive correlation( >+ 0.5 or < - 0.5) 
The analysis of results revealed that  
1. The correlation between PAAT and PASP was significant only in mild and 
moderate degrees of PH while it was not so in severe PH.  
2. There was significant correlation between PAAT and MPAP in all degrees of PH. 
3. Correction for heart rate did not affect the above results. 
4. In contrast, correlation between TRVmax derived EPASP and PASP was significant 
in moderate and severe PH, while it was not so in mild PH. 
5. Correlation between PR derived PADP and invasively obtained PADP was also 
significant in moderate and severe PH, but not so in mild PH. 
 
 
Table 20: Correlation between Echo derived findings and Invasively obtained  findings 
in different types  of RV diastolic function 
 
Correlation between 
Correlation Coefficient 
Normal Impaired 
relaxation 
Pseudo 
normal filling 
Echo based PAAT & Invasive PSAP -0.86 -0.94 -0.90 
Echo based PAAT & Invasive MPAP -0.89 -0.97 -0.95 
Echo based PAAT/RVET & Invasive PSAP -0.86 -0.96 -0.91 
Echo based PAAT/RVET & Invasive 
MPAP 
-0.88 -0.87 -0.92 
Echo based ESPAP & Invasive PSAP 0.98 0.83 0.96 
Echo based PREDP & Invasive PDAP 0.99 1.0 0.92 
The numbers marked in bold show positive correlation( >+ 0.5 or < - 0.5) 
The strength of correlation between PAAT and PASP and between PAAT and MPAP 
was strong among the different groups with normal diastolic function, impaired 
relaxation and pseudonormal filling  and this  was not affected by correction for heart 
rate and was comparable to the strength of correlation between EPASP and invasively 
measured PASP.  
 
 
Table 21: Correlation between Echo derived findings and Invasively obtained  findings 
in in normal and abnormal RV systolic function 
Correlation between Correlation Coefficient 
Normal systolic 
function 
Systolic 
dysfunction 
Echo based PAAT & Invasive PSAP -0.90 -0.89 
Echo based PAAT & Invasive MPAP -0.95 -0.73 
Echo based PAAT/RVET & Invasive PSAP -0.90 -0.90 
Echo based PAAT/RVET & Invasive MPAP -0.93 -0.64 
Echo based ESPAP & Invasive PSAP 0.95 0.91 
Echo based PREDP & Invasive PDAP 0.96 0.93 
The numbers marked in bold show positive correlation( >+ 0.5 or < - 0.5) 
The strength of correlation between PAAT and PASP and between PAAT and MPAP 
remained strong after excluding patients with RV systolic dysfunction  and also  was not 
affected by correction for heart rate and remained comparable to the strength of 
correlation between EPASP and invasively measured PASP. The small(9 of 53) group of 
patients with RV systolic dysfunction also showed a slightly weaker, yet significant 
correlation among the various above mentioned parameters analysed. 
 
 
DISCUSSION 
TTE has been proved to be an important method in the noninvasive assessment 
of pulmonary artery pressures in a wide range of diseases.30,31,45,48,56,57,58 The most 
widely accepted and employed transthoracic echocardiographic method for the 
derivation of pulmonary artery pressures relies on measurement of TRVmax. 
Oftentimes, TR is not sufficient to perform this measurement, as shown by the fact that 
9.4% of patients in our study of patients with PH of varied etiologies had insufficient TR 
for EPASP estimation. Many other techniques had been proposed to assess the 
pulmonary hemodynamics.  
Kitabatake et al.58 showed that PAAT correlates strongly with MPAP and its 
logarithm (r = 0.82 and 0.88, respectively) as measured by cardiac catheterization. They 
also showed that PAAT corrected for RVET, a method of adjusting for the heart rate, 
slightly strengthened the correlation between PAAT and MPAP. 
In a study that followed, Dabestani et al.57 described the same relationship and 
derived  the following equation: MPAP = 73 - (0.42 x PAAT). In contrast to Kitabatake et 
al., they showed that both the logarithmic transformation of MPAP and the correction 
for RVET did not improve the accuracy of estimating the MPAP using PAAT. Together, 
these two studies established the usefulness of Doppler derived measurements of 
pulmonary arterial forward flow in providing an accurate estimate of MPAP. 
RV isovolumic relaxation time (RVIRT) and the tissue Doppler-derived RVIRT48 
have also been examined in previous studies to determine their usefulness in estimating 
 
 
the systolic pulmonary artery pressure. Brechot et al.48 had studied 26 patients by trans 
thoracic echocardiography and right heart catheterization. Tissue Doppler-derived 
RVIRT correlated strongly with PASP and was able to exclude reliably the diagnosis of 
pulmonary arterial hypertension. But, prolonged RVIRT was not specific for pulmonary 
hypertension. RVIRT-derived PASP also did not correlate with the catheter-based values. 
Despite the above important publications, the use of PAAT in clinical practice 
had so far remained relatively limited. This is mainly because the vast majority of the 
publications reporting echocardiographic pulmonary artery pressure estimates had 
relied on TRVmax-derived EPASP. As such, physicians who rely on TTE for pulmonary 
artery pressure measurement have developed a familiarity with and also a preference 
for peak systolic, and not mean, pulmonary artery pressure values. 
Despite the well-known and established role of invasively measured MPAP 
values in the diagnosis and management of PH,  TRVmax derived EPASP is used more 
often than PAAT derived MPAP. This inspite of the fact that in a recent series of studies, 
a significant number of patients with systolic pulmonary artery pressures >50 mm Hg 
had mild TR or less, making the reliance on TRVmax for the measurement of EPASP 
unfeasible.61 Our data indicate that PAAT could be a very important tool in deriving the 
EPASP and the EMPAP in the absence of sufficient TR and also demonstrate that PAAT 
can be used as a reliable alternative method for the derivation of both the EPASP and 
the EMPAP. 
 
 
Our results and their implication on the usefulness of TTE in assessing the 
pulmonary hemodynamics non invasively can be summarized as follows. First, TRVmax 
was not measurable in 9.4% of patients, while PAAT was measurable in 100%. Of our 
patients with PH. This percentage may increase further if patients with borderline 
elevation of PA pressures were included in the study. Although saline injection may be 
useful in augmenting a weak or immeasurable TR signal,  this method involves the 
insertion of an intravenous line and requires coordinated injection of agitated saline and 
color Doppler interrogation of the flow across the tricuspid valve. Though this technique 
may be useful, it is both resource and time consuming and thus shall not be optimal in a 
busy echocardiography laboratory. This underscores the need for an approach to 
pulmonary artery pressure measurement that is independent of the presence of TR and 
also justifies the use of a PAAT dependent method in the clinical echocardiography 
laboratory. 
As with a previous study by Yared et al63, we observed a strong and inverse 
correlation between PAAT and  invasively obtained PASP among a cohort of patients 
with PH and with a wide range of PASP values. There was also a strong inverse 
correlation between PAAT and invasively derived MPAP values. This is in concurrence 
with previous studies57,58.  
The strength of the correlation was comparable to the correlation between TRPG 
derived EPASP and the invasively measured PASP (-0.93 Vs 0.94). Hence we propose that 
if studied  in a larger cohort, this relationship can be quantified to find a regression 
 
 
formula, as in the previous study by Yared et al63, and thus make it feasible to derive not 
only the MPAP but also the PASP from the PAAT, in patients without sufficient TR too, so 
that the pulmonary hemodynamics can be accurately measured non invasively in a 
larger percentage of patients. 
Several technical and physiologic issues pertaining to this study deserve 
mention. Though proximal pulmonary artery forward flow, as assessed by pulsed-wave 
Doppler, has a characteristic pressure-dependent pattern (i-e) the acceleration time 
becomes shorter as the pulmonary artery pressure increases, other factors, namely the 
heart rate, RV function, cardiac output, and the imaging technique, may affect its 
duration.30 We accounted for the potential impact of heart rate variation in our study by 
correcting for heart rate with the RVET. Similar to other previously published studies,57 
we found these corrections to be unnecessary.  
Because we were not able to control for cardiac output in our study, we cannot 
comment as to how cardiac output affected our findings, and so we remain uncertain 
about the accuracy of PAAT for deriving EPASP in patients with high cardiac output due 
to conditions like exercise or systemic vasodilation.  
It has been shown that RV function can affect PAAT .  RV systolic dysfunction 
tends to lengthen the PAAT.64 In our study population, only 9 patients had RV 
dysfunction, and their removal and reanalysis of data did not affect our correlation 
results. Because of the small number of patients with RV dysfunction in our study, we 
 
 
propose that our derivations from the study may not be accurate in patients with RV 
systolic dysfunction. 
 The imaging technique plays an important role in the measurement of PAAT 
that accurately reflects pulmonary pressure. Proper placement of the Doppler sample 
volume in the middle of the pulmonary artery and also its accurate alignment to the 
long axis of the main pulmonary artery are essential.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS 
Limitations in this study are that  
 
1. The number of cases include in our study was small 
2. We did not examine the performance of PAAT for the estimation of EPASP in 
conditions with high cardiac output, like volitional exercise or systemic 
vasodilation as in sepsis. 
3. The proportion of cases due to lung disease, chronic thrombo embolic PH and 
due to idiopathic PH was small in our study. 
4. Though the number of cases with RV systolic dysfunction, as measured by TAPSE, 
tricuspid s’ and RV fractional area change was small in our study, there were a 
significant number of cases with RV diastolic dysfunction. The measurement of 
RV Tei index which is a marker of global RV function would have thrown more 
light on the impact of global RV function on the performance of PAAT for the 
derivation of MPAP and PASP. This was not done in our study.  
5. The placement of Doppler sample volume during pulse-wave and continuous-
wave Doppler examination at the center of the pulmonary artery is crucial to 
optimize the laminar flow pattern. Any  deviation from this technique, like 
placing the sample volume close to the pulmonary artery wall, may change this 
flow pattern and thus render it unreliable. 
 
 
 
CONCLUSION 
 
PAAT is easily measurable in patients with pulmonary hypertension and strongly 
correlates with the values of pulmonary artery systolic pressure and the mean 
pulmonary artery pressure obtained by right heart catheterisation in a small population 
of patients with pulmonary hypertension due to a wide spectrum of illness, who 
underwent Trans Thoracic Echocardiographic (TTE) examination. This is comparable to 
the strong correlation between the previously well established method of deriving the 
EPASP from TRVmax and the invasively derived PASP. Adoption of a novel method of 
determining EPASP from PAAT shall increase significantly the number of patients in 
whom TTE can be used for the assessment of pulmonary hemodynamics non invasively. 
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PRESENTATION:               Chest pain                                                           Pedal  edema 
                                            Dyspnoea                                                            Abd distension 
                                            Syncope                                                               Oliguria 
                                            Palpitation                                                          Fatigue 
                                            Other 
PAST  ILLNESS:                 Diabetes/SHT/COPD 
                                           ACS/ CVA 
                                           RHD/Other 
PERSONAL HISTORY:     Smoking/ Addictions 
                                          Occupation 
MENSTRUAL HISTORY: 
CLINICAL FEATURES:     GE – 
                                          BP:                                                    PULSE: 
                                          CVS: 
                                          RS: 
                                          ABD:                                                CNS: 
 
Clinical Diagnosis: 
 
Investigations:                Hb:                   TC:                         DC: P     L      E     M  
 
 
 
PERFORMA 
 
NAME:                                            AGE/SEX:                              HT:                        WT:                     
 
CD NO.                                            IP/OP no.                                                            CCL NO.  
 
 
D.O.A:                                            D.O.D:                                                                   D.O.E: 
 
 
                                          RBS:                  Bl Urea:                Sr. Creatinine:  
Others: 
ECG:               Rate:                             Rhythm:                       P wave:                            PR int: 
                       QRSD:                          QRS axis:                       ST:                                    T : 
ECHO data: 
                        LVID d:                                                 LVID s:                                LVEF: 
                        LVOT dia:                                            LVOT VTI:                            HR:               C.O. :                         
TR-derived values 
TR Vmax (cm/sec)    RA/RV gradient (mm Hg) :  
EPSPAP (mm Hg)  
Pulmonary artery–derived values 
PAAT (ms)                               MPAP                                        PAVmax (cm/sec)  
RVET (msec)                           PAAT/RVET (m/sec2)  
RVOT  VTI                               PR EDP 
RV Chamber dimensions 
RV basal diameter cm                                         RV subcostal wall thickness 
RVOT PSAX distal diameter                               RVOT PLAX proximal  diameter 
IVC  cm/collapse                                                  RA pr: 
RV Systolic function 
TAPSE cm                        Tricuspid s’ cm/s                     FAC%                           
RV  Diastolic function 
E/A ratio —                                                                E/E’ ratio —  
Deceleration time (ms)  
Right Heart Study: 
 
 
Approach:                                          Catheters: 
RA pr:                                                 RVSP:                                                  RVEDP:             
PASP:                                                  PADP:                                                 MPAP:      
PAWP:            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MASTER CHART 
S.No Name Age/Sex History Pulse Hb ECG Diagnosis 
      CP S.O.B RVF Other         
1 Selvi 42/F N N N N 84 10.5 AF Cor AVF 
2 Ganesan 40/M Y Y N Old PT 80 16.1 RVH/RBBB ASD/PHT 
3 Pandiaraj 21/M Y Y Y S/P CMC 78 10.7 RVH RHD 
4 Arumugam 60/M N Y N K/C RHD 72 11.7 LAA/RAD RHD 
5 Sundari 32/F N Y N   112 11.6 ST CPTE 
6 Ganesan 55/M N Y N K/C RHD 64 11.6 LVH RHD 
7 Sneha 14/F N N N RRTI 86 10.2 BVH VSD/PHT 
8 Gopalakrishnan 60/M N Y N K/C RHD 66 10 LVH RHD 
9 Jothimani 13/F N Y N RRTI 108 10.1 BVH VSD/PDA/SMR 
10 Booma 45/F N Y N RHD 98 12.3 LVH RHD 
11 Anbu 32/M Y Y N RF 72 13 LAA/RVH RHD 
12 Vellaisamy 45/M Y Y N N 72 13 LAA/LVH RHD 
13 Davamani 27/M N Y N N 70 13.5 IRBBB ASD/PHT 
14 Palaniammal 45/F Y N N Fever 100 10.6 RVH SScl 
15 Sangeetha 17/F Y Y N RF 80 10 N RHD 
16 Selsi 18/F N Y N N 67 9 RVH PPH 
17 Annapillai 35/F N Y N Scoliosis 100 11 RVH/AF RHD 
18 Nageswari 30/F Y Y N RRTI 92 12.8 CRBBB ASD/PHT 
19 Karpagavalli 15/F Y Y N N 75 16 RVH PPH 
20 Rekshalin Mary 26/F N Y N Postpartum 88 9 RAD ASD/PHT 
21 Vanniappan 65/M Y N N SHT 80 15.6 CRBBB/RAD ASD/PHT 
 
 
22 Latha 24/F N Y N Postpartum 78 13.1 RVH ASD/PHT 
23 Dhanushiya 16/F N Y N RRTI 64 14.6 CRBBB/LVH AVCD 
24 Poomayil 42/F N Y N N 100 19.8 N CPTE 
25 Ammaniammal 45/F N Y N Raynaud 92 9.9 RVH SScl 
26 Chinnapillai 38/F N Y N N 100 12  ST changes CPTE 
27 Nagarathinam 45/F N Y N RHD 98 12 LVH RHD 
28 Karuppiah 24/M Y Y Y S/P CMC 82 10.9 RVH RHD 
29 Angaian 42/M Y Y N Old PT 80 16 RVH ASD/PHT 
30 Gandhimathi 13/F N Y N RRTI 86 10.8 BVH VSD/PHT 
31 Bhagyam 38/F Y N N Fever 100 10 RVH SScl 
32 Chandra 21/F Y Y N RF 84 10.8 N RHD 
33 Sivalingam 60/M N Y N RHD 72 11.7 LAA/RAD RHD 
34 Vasanthi 20/F N Y N N 68 9.8 RVH Cystic lung 
35 Meera 15/F N Y N RRTI 104 10 BVH PDA 
36 Muthiah 55/M N Y N RHD 64 11.6 LVH RHD 
37 Chellammal 37/F N Y N S/P CMC 98 11 RVH/AF RHD 
38 Pandiammal 33/F Y Y N RRTI 90 12 CRBBB ASD/PHT 
39 Ammasi 51/M N Y N RHD 68 11.9 LVH RHD 
40 Jayalakshmi 21/F Y Y N N 78 15.8 RVH PPH 
41 Mohamed Siddique 33/M N Y N RF 70 13 LAA/RVH RHD 
42 Subramanian 45/M Y Y N N 78 13.1 LAA/LVH RHD 
43 Sivagami 28/F N Y N Postpartum 86 9.8 RAD ASD/PHT 
44 Gangaraman 29/M N Y N N 71 11.8 RVH ILD 
45 Indrani 26/F N Y N Postpartum 82 13.1 RVH ASD/PHT 
46 Rajapandian 28/M N Y N N 74 13.5 IRBBB ASD/PHT 
47 Muthupetchi 17/F N Y N RRTI 68 14.6 CRBBB AVCD 
48 Saroja 45/F N Y N Raynaud 96 10 RVH SScl 
 
 
49 Alagusundaram 65/M Y N N N 82 15.8 CRBBB ASD/PHT 
50 Kamatchi 19/F N Y N N 70 9.9 RVH PPH 
51 Usharani 18/F Y Y N N 80 16.1 RVH PPH 
52 Thirukkammal 23/F Y Y N RF 78 10.9 N RHD 
53 Boopalan 31/M N Y N N 78 12.8 IRBBB ASD/PHT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
    S.No Name RV dimension       cm Echo hemodynamics  
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1 Selvi 4.1 3.3 2.8 0.5 37 3 40 85 249   37.3 
    2 Ganesan 4 3.8 3.5 0.9 78 8 86 77 285 18 47.7 
    3 Pandiaraj 4.1 3.8 3 0.8 63 4 66 86 246 25 37 
    4 Arumugam 3.6 3.4 2.8 0.8   5   77 295   42 
    5 Sundari 3.3 3.3 2.5   36 5 41 94 240   32 
    6 Ganesan 2.9 2.4 2 0.5 34 5 39 100 244   28 
    7 Sneha 3.4 2.7 2.5 0.6 93 5 98 64 278 18 50.3 
    8 Gopalakrishnan 2.8 2.3 2 0.6   8   90 246   34 
    9 Jothimani 3.1 2.7 2.4 0.7 99 5 104 57 285   54.6 
    10 Booma 2.8 2.6 2.4 0.6 33 5 38 96 246   31 
    11 Anbu 3.2 2.4 2 0.6 32 5 37 90 248   34.2 
    12 Vellaisamy 3.9 3.4 2.9 0.6 54 5 59 87 239 15 36 
    13 Davamani 4.1 4.1 4 0.7 40 5 45 96 246   30.4 
    14 Palaniammal 3.8 3.3 3.1 0.5 60 3 63 65 282   50.2 
    15 Sangeetha 3 2.6 2.4 0.6 73 5 78 64 294   50.3 
    16 Selsi 2.8 3.2 2.8 0.6 101 5 106 60 289 30 52.8 
    
 
 
17 Annapillai 3.9 2.5 2.4 0.8 85 5 100 67 279   49 
    18 Nageswari 3.8 3.2 2.9 0.7 66 5 71 81 271 20 39.7 
    19 Karpagavalli 3.2 2.6 2.6 0.7 94 5 99 66 275 37 49 
    20 Rekshalin Mary 3.7 3 2.8 0.6 46 5 51 89 240 18 34.8 
    21 Vanniappan 3.5 2.6 2.3 0.8 60 5 65 70 282   46.6 
    22 Latha 4.2 3.7 3.2 0.6 91 5 96 60 289 35 52.8 
    23 Dhanushiya 3.7 3.4 3.4 0.7 98 8 106 63 288   50.9 
    24 Poomayil 3.3 3.4 2.5 0.6 36 5 41 94 240 10 32 
    25 Ammaniammal 3.7 3.4 3 0.6 58 5 63 74 285   44.1 
    26 Chinnapillai 3.7 3.3 2.5 0.6 48 5 53 90 240   34.2 
    27 Nagarathinam 2.8 2.6 2.4 0.6 33 5 38 96 246   31 
    28 Karuppiah 4.1 3.8 3 0.8 63 5 68 85 254 28 37.4 
    29 Angaian 4 3.8 3.5 0.9 78 8 86 77 249 18 47.7 
    30 Gandhimathi 3.4 2.7 2.7 0.6 93 5 98 63 282 18 50.8 
    31 Bhagyam 3.8 3.3 3.1 0.6 59 5 64 66 278   49.7 
    32 Chandra 3 2.6 2.4 0.6 79 5 84 64 262   50.3 
    33 Sivalingam 3.6 2.4 2.8 0.6   5   77 285   42 
    34 Vasanthi 3.2 3.2 2.8 0.6 81 5 86 60 289 32 52.8 
    35 Meera 3.4 2.9 2.8 0.7 93 5 98 57 282   54.6 
    36 Muthiah 2.9 2.4 2 0.5 35 5 40 101 250   27.8 
    37 Chellammal 3.9 2.6 2.6 0.9 84 15 99 67 279   49 
    38 Pandiammal 3.9 3.5 3.2 0.7 65 5 70 81 270 22 39.7 
    39 Ammasi 3 2.6 2.2 0.5   5   100 292   28 
    40 Jayalakshmi 3.2 2.6 2.6 0.7 94 5 99 66 275 36 49 
    41 Mohamed Siddique 3.2 2.4 2.1 0.6 32 5 37 90 243   34.2 
    42 Subramanian 3.9 3.4 2.9 0.6 53 5 58 87 240 18 36 
    43 Sivagami 3.7 3.1 2.8 0.6 46 5 51 89 248 18 34.8 
    
 
 
44 Gangaraman 3.3 3.2 2.9 0.6 90 5 95 60 280 32 52.8 
    45 Indrani 4.2 3.7 3.2 0.6 90 5 95 60 289 36 52.8 
    46 Rajapandian 4.3 4.1 4 0.7 40 5 45 96 246   30.4 
    47 Muthupetchi 3.7 3.4 3.3 0.7 96 6 102 63 287   50.9 
    48 Saroja 3.7 3.4 3.1 0.6 58 5 63 74 285   44.1 
    49 Alagusundaram 4 3.2 2.8 0.8 61 5 66 70 280   46.6 
    50 Kamatchi 3.2 3 2.9 0.6 93 5 98 60 280 31 52.8 
    51 Usharani 3.6 2.9 2.8 0.7 100 5 105 66 275 31 49 
    52 Thirukkammal 2.1 2.7 2.5 0.6 68 6 74 64 262   50.3 
    53 Boopalan 4.1 4.1 4 0.7 43 5 48 90 240   34.2 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
S.No Name RV Sys Fn RV dia fn Invasive Pressures (mmHg) 
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1 Selvi 2 15 58   4.6 165 9 50 22 37 51 10 18 
2 Ganesan 2.6 17 60 0.75 4.75 194 8 70 24 44 66 15 12 
3 Pandiaraj 0.9 6.9 22 0.79 9.5 106 18 58 28 39 61 3 4 
4 Arumugam 1.9 12 50 0.71 6.75 204 16 70 28 41 69 5 6 
5 Sundari 2.7 17 54 0.6 5.2 140 9 39 17 30 40 12 9 
6 Ganesan 3 13 53 1.5 6.8 180 18 38 18 29 42 10 6 
7 Sneha 2.8 17 49 1.28 6.8 113 8 104 26 48 99 10 8 
8 Gopalakrishnan 1.8 11 40 1.26 8.6 165 22 55 25 35 55 12 9 
9 Jothimani 1.8 14 41 1.32 5 120 21 90 40 55 100 10 12 
10 Booma 2.2 16 50 0.84 4.72 128 18 51 18 31 47 10 6 
11 Anbu 2.4 14 51 1.4 3.25 148 32 48 29 37 52 9 8 
12 Vellaisamy 1.9 15 59 1.5 8 109 26 50 26 35 46 3 5 
13 Davamani 2.9 15 50 1.75 9.8 137 8 43 18 31 45 8 5 
14 Palaniammal 1.9 10 35 1 5.5 106 8 61 24 38 63 10 10 
15 Sangeetha 2.5 14 45 1.21 8.8 194 27 73 31 51 72 8 8 
16 Selsi 1.4 10 34 1.51 13 204 13 96 39 57 97 10 11 
17 Annapillai 1.3 10 35   8 201 30 106 31 49 100 10 11 
18 Nageswari 1.2 7 27 1 6.5 280 10 78 24 42 81 12 11 
 
 
19 Karpagavalli 1.7 12 41 1.2 3.9 244 9 100 38 52 104 12 12 
20 Rekshalin Mary 2.9 19 56 1 6.2 243 8 55 24 34 58 11 10 
21 Vanniappan 2.7 16 52 0.6 5.8 342 10 72 37 49 77 12 11 
22 Latha 1.9 12 40 0.8 6.4 180 9 88 39 55 92 9 8 
23 Dhanushiya 1.9 10 34 1.1 4.8 201 9 98 29 49 102 8 8 
24 Poomayil 2.7 17 55 0.8 5.8 200 9 39 17 30 40 12 9 
25 Ammaniammal 1.7 13 43 1.1 5.7 126 8 69 31 45 68 9 8 
26 Chinnapillai 2.4 18 58 0.6 5.8 138 9 48 21 33 50 12 9 
27 Nagarathinam 2.2 16 57 0.84 4.7 129 18 50 18 32 47 10 7 
28 Karuppiah 0.9 6.1 27 0.8 8.7 106 18 58 29 38 61 4 4 
29 Angaian 2.6 17 59 0.75 5.5 196 8 70 24 44 66 15 12 
30 Gandhimathi 2.8 16 57 1.27 6.4 113 8 104 26 48 99 10 8 
31 Bhagyam 1.9 10 35 1.1 5.8 120 9 64 24 39 68 9 8 
32 Chandra 2.5 14 47 1.2 7.8 194 27 74 29 50 76 8 8 
33 Sivalingam 1.9 12 42 0.71 6.75 206 16 70 28 41 69 5 6 
34 Vasanthi 1.4 10 34 1.6 10 204 13 96 39 55 97 10 11 
35 Meera 1.8 14 49 1.32 5 120 9 92 43 58 92 10 9 
36 Muthiah 3 13 45 1.5 6.8 180 15 39 18 28 44 10 11 
37 Chellammal 1.3 10 34   8 201 27 108 30 47 102 10 11 
38 Pandiammal 1.2 7 27 1 6.5 280 10 72 24 42 76 12 11 
39 Ammasi 2.9 17 57 1.2 6 171 16 40 17 29 42 10 10 
40 Jayalakshmi 1.7 12 40 1.2 3.9 244 9 100 38 52 102 10 10 
41 Mohamed Siddique 2.4 14 47 1.3 3.25 148 30 49 28 38 52 9 8 
42 Subramanian 1.9 15 50 1.5 8 109 26 50 20 35 46 4 4 
43 Sivagami 2.9 20 60 1 6.2 243 8 55 24 34 58 11 10 
44 Gangaraman 1.6 13 44 1.53 9.1 201 10 92 39 54 97 8 8 
45 Indrani 1.9 14 47 0.8 6.4 180 9 88 39 55 90 9 8 
 
 
46 Rajapandian 2.9 15 54 1.76 9.8 137 8 43 18 31 45 8 7 
47 Muthupetchi 1.4 10 35 1.1 6.8 204 9 98 31 38 100 10 9 
48 Saroja 1.7 13 45 1.1 5.7 126 8 69 31 45 67 8 8 
49 Alagusundaram 2.7 16 55 0.6 5.8 142 11 70 37 48 77 12 11 
50 Kamatchi 1.7 14 49 1.4 9.4 204 9 90 39 55 93 10 11 
51 Usharani 1.8 14 50 1.2 4.2 240 9 96 36 50 99 9 8 
52 Thirukkammal 2.6 17 58 1.21 8.8 192 24 73 30 49 76 8 8 
53 Boopalan 2.6 14 51 1.61 6.8 120 8 49 19 33 50 8 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE DISTRIBUTION OF THE STUDY 
POPULATION
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Serotonin synthesis via tryptophan hydroxylase 1 acts in a paracrine fashion on underlying 
PASMCs. This may contribute to contraction and  increase the expression of nuclear growth 
factors leading to proliferation. Serotonin may also stimulate 5-hydroxytryptamine (5-HT) 1A 
and 2B receptors to induce contraction and ROS, ROCK, and MAPK activation.  
Signaling by wild-type BMPRII involves heterodimerization with the transmembrane serine-
threonine kinases type I BMPR-IA and BMPR-IB receptors at the cell membrane. On ligand 
binding, the constitutively active BMPR-II phosphorylates the type I receptor. Activated type I 
receptors phosphorylate the cytoplasmic signaling proteins known as receptor-mediated 
Smads (R-Smads) 1, 5, and 8. These complex with Smad4 and translocate to the nucleus, 
where they activate downstream target genes such as the inhibitors of DNA binding 3 (Ids), 
which inhibit proliferation.  
Serotonin may antagonize the antiproliferative  BMPR-II/Smad  pathway, inhibit Id3 
activation, and facilitate proliferation.          (−) = inhibitory effect. 
Molecular mechanisms of cellular proliferation–mediated remodeling in PH 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This schematic features inflammatory mediators, cells, and mechanisms involved in pulmonary 
vascular remodeling as well as potential therapeutic targets.  
(bcl2 = B-cell lymphoma 2; CCL2 = chemokine (C-C motif) ligand 2; CCL5 = chemokine (C-C motif) 
ligand 5 or RANTES (regulated upon activation, normal T cell expressed and secreted); CX3CL1 = 
chemokine (C-X3-C motif) ligand 1 (fractalkine); CX3CR1 = chemokine (C-X3-C motif) receptor 1; 
DC = dendritic cells; FB = fibroblasts; FGF = fibroblast growth factor; 5-HT = serotonin; HIV-1 = 
human immunodeficiency virus 1; IgG = immunoglobulin G; MO = monocyte; PGI2 = prostacyclin; 
ROK = rho kinase.) 
 
(From Hassoun PM, Mouthon L, Barbera JA, et al: Inflammation, growth factors, and pulmonary 
vascular remodeling. J Am Coll Cardiol 54:S10, 2009.) 
Molecular mechanisms of inflammation-mediated remodeling in PH 
  
 
 
 
Various mediators induce tissue factor TF expression through activation of their 
receptors. Induction of TF primarily occurs at the transcriptional level, resulting in an 
increase in TF mRNA and, eventually, in TF protein expression. TF is distributed in three 
cellular pools as cytoplasmic TF, surface TF, and encrypted TF. Moreover, TF-containing 
microparticles are released from the cell. Alternative splicing results in a soluble 
secreted form of TF (asTF).  
(CD40-L = CD40-ligand; H1 = histamine H1 receptor; 5-HT2a = 5-hydroxytryptamine 2a 
receptor; IL-1-R = interleukin-1 receptor; KDR = VEGF receptor 2; LPS = 
lipopolysaccharide; PAR = protease-activated receptor; TLR-4 = Toll-like receptor 4; TNF-
R = tumor necrosis factor receptor.) 
 
(From Steffel J, L?scher TF, Tanner FC: Tissue factor in cardiovascular diseases: 
Molecular mechanisms and clinical implications. Circulation 113:722, 2006.) 
 
 
 
Molecular mechanisms of thrombosis-mediated remodeling in PH 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The process may be initiated by abnormal gene transcription and expression of Kv channels. 
Resultant reduction of Kv currents [IK(v)] causes membrane depolarization and opens voltage-
gated Ca2+ channels. Increased Ca2+ influx through sarcolemmal Ca2+ channels and Ca2+-
induced Ca2+ release from intracellular Ca2+ stores (mainly sarcoplasmic reticulum [SR]) raise 
cytoplasmic Ca2+ concentrations ([Ca2+]cyt), which triggers pulmonary vasoconstriction. 
Endothelium-derived relaxing factors (EDRFs) may participate in regulating Em and [Ca2+]cyt 
through activation of K+ (KCa and Kv) channels and/or inhibition of voltage-gated Ca2+ 
channels in PASMCs.                       (+) = increase (or enhance); (−) = decrease (or inhibit). 
(From Yuan J, Aldinger A, Juhaszova M, et al: Dysfunctional voltage-gated K+ channels in 
pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. 
Circulation 98:1400, 1998.) 
Molecular mechanisms of vasoconstriction-mediated remodeling in PH 
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INTRODUCTION Two decades ago pulmonary hypertension (PH) was seen as a serious illness
with a survival of 2.8 years from its diagnosis. Significant progress has been made in this field in the
last ten to fifteen years in the understanding of the pathophysiology and also the treatment of PH. In
the past, even though physicians diagnosed PH, treatment of this condition was not rewarding and
patients almost always succumbed to the disease. The discovery of prostacyclin by Sir John Vane
has since made a revolution in the treatment of PH1. PH is a disease that results from reduction in the
quantity of blood flowing across the pulmonary circulation, that causes an increase in pulmonary
vascular...
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